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ABSTRACT 
Song, Yang. Ph.D., Purdue University, December 2015. Acid-base Interactions in 
Amorphous Solid Dispersions: Formulation Strategy for Tyrosine Kinase Inhibitors. Major 
Professors: Stephen Byrn and Rodolfo Pinal. 
 
Using the amorphous state of APIs has become a very beneficial strategy to 
overcome the solubility challenge faced with an increasing number of newly discovered 
drug candidates or available APIs. Given the inherent physical instability of amorphous 
materials, pharmaceutical products are usually formulated by dispersing APIs into 
polymers utilizing primarily hot melt extrusion or spray drying. The stabilization 
mechanisms have been discussed over the las three decades. More recently, it has been 
widely accepted that strong intermolecular interactions between drug and polymer are very 
important for maintaining the physical stability of the amorphous API. However, the nature 
of acid-base interaction in the stability of amorphous solid dispersions (ASDs) has not been 
fully explored. Among the novel small molecule anticancer drugs, tyrosine kinase inhibitor  
family has led in short time to 20 marketed products. Most of these TKIs are structurally 
related, and exhibit low to medium bioavailability because of poor water solubility.  
This dissertation is based on the hypothesis that amorphous solid dispersions 
exhibiting strong acid-base interactions between acidic polymers and basic TKIs can be
vii 
 
   
 exploited to formulate more bioavailable formulations of TKIs. In this study, two TKIs 
were used as model compound and formulated as ASDs with various acidic polymers to 
test the hypothesis. In addition, a new methodology, using the powerful analytical 
technique of XPS, was developed to investigate detail the nature of acid-base interaction 
of TKIs in ASDs. The most common industrial manufacturing processes for formulation 
of amorphous solid dispersion are spray-drying and hot melt extrusion. However, there is 
very limited published information discussing the different effects of these two methods 
on the properties of formulated ASDs, especially regarding the nature of the acid-base 
interaction within the TKI and polymer. This study used lumefantrine as a model 
compound and formulated it with five acidic polymers to explore the manufacturing effects 
on the acid-base interactions in ASDs. While not commonly used for producing ASDs, 
ball-milling also can lead to amorphous systems, and the final part of this study investigated 
how this process impacts the acid-base interactions within ASDs.
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CHAPTER 1.INTRODUCTION 
1.1 Amorphous State 
With the use of high throughput and combinational screening tools in drug 
discovery, the increasing number of poorly soluble drugs with low bioavailability has 
become a growing challenge in drug formulation development. Besides salt formation, co-
crystal formation, and nano-particle formulation, one of the most useful techniques to 
increase the solubility and accelerate the dissolution rate of a drug is exploiting the 
amorphous state. Amorphous solids can be formed by four common methods: vapor 
condensation, precipitation from solution, super-cooling of a melt and milling or 
compaction of crystals.1 Amorphous solids have short-range order and do not possess the 
three-dimensional long-range order that typically exists in their crystalline counterparts.1 
As a result, the amorphous state of a API has a higher free energy, enthalpy, entropy, and 
a greater molecular mobility than its crystalline form as presented in Figure 1. The result 
from these attributes is a higher solubility and faster dissolution rate.2 
However, the high energy character of the amorphous state renders amorhous 
compounds physically unstable and often chemically unstable as well. Amorphous drug
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compounds have a tendency to revert to their crystalline state in the solid state, and to 








   
1.2 Crystallinity of Amorphous Solids 
Amorphous drugs will always have the tendency to recrystallize during preparation, 
storage and administration because they are thermodynamically less stable than their 
crystalline counterparts.1, 3 Recrystallization includes two processes: nucleation and crystal 
growth.4 Starting from the supersaturated state either in the solid state or the solution state, 
the amorphous APIs tends to form small clusters/ aggregates (nucleation), which then grow 
to observable crystals (crystal growth).5 Figure 2 shows how the important factors 








   
1.3. Amorphous Solid Dispersion 
Over the last two decades, solid dispersions of APIs in polymer carriers have been 
widely used to formulate amorphous drugs. Different techniques including hot melt 
extrusion, spray drying, and freeze drying are available to prepare amorphous solid 
dispersions. Various types of polymers have been utilized as carriers in pharmaceutical 
development. The most common types of polymers used in ASDs are either aqueous 
soluble under all pH conditions or soluble only under neutral or alkaline pH conditions 
(thus showing so-called enteric properties6). The enteric polymers are poorly soluble in the 
gastric fluid and were originally used in modified release systems6  in which they can 
deliver API to a specific section of the GI tract while avoiding the gastric degradation of 
specific APIs.7, 8 The typical use of enteric polymers consists of applying them to coat the 
surface of the formulations such as microspheres, tablets, beads or pellets.8 Enteric 
polymers typically consist of ionic functional groups, which can ionize under specific pH 
conditions, and are thus often referred to as ionic polymers.8  In 1984, cellulose acetate 
phthalate was the first enteric polymer used to formulate a solid dispersion. It was 
developed by Hasegawa for an insoluble API, nifedipine.9 With the use of enteric solid 
dispersions, the oral absorption of many poorly water soluble compounds have been 
achieved 10, 11 because of the delayed dissolution and supersaturation until the drug reaches 
- the  small intestine.8, 12 The control mechanism of an enteric polymer depends on its 
structure. Often, these polymers consist of a hydrophilic monomeric structure, like 
methacrylic acid, and a lipophilic structure, like the methyl methacrylate.13 It is 
hypothesized that the behavior of enteric polymers is directly related to the protonation 
5 
  
   
state of the polymer: the acidic groups became ionized at a higher pH, their conformations 
changed and expanded due to the repulsion between the negative charges. In contrast, the 
carboxylic groups remain unchanged at a lower pH. Some polymer conformations can lead 
to the precipitation of the copolymer. 13  Besides their enteric properties, ionic polymers 
have been found to be very useful in stabilizing amorphous materials, both in the solid state 
and in supersaturated solutions. 
1.3.1 Structure of Amorphous Solid Dispersions 
There is substantial interest in the structure of amorphous dispersions. In particular, 
as it relates to miscibility and drug-polymer intermolecular interactions. As early as 1972, 
Riegelman and Chiou discussed the structure of neutral amorphous dispersions.  They 
described solid solutions as containing a homogeneous mixture of components.  
Amorphous dispersions containing salts formed by the interaction of a polymer and an 
acidic or basic drug are likely amorphous, since essentially all of the polymers used to form 
the dispersions are amorphous and contain a non-ordered content of ions.  Thus, one would 
expect that the salts formed would be amorphous because they would be associated with 
the non-ordered distribution of ions in the polymer and thus be in an arrangement that lacks 
long range order. 
In the last two years solid state NMR has emerged as a powerful tool for 
determining the structure of amorphous dispersions. Utilization of T1 relaxation 
individually or combined with T1 measurements has been used to provide important 
information on whether the dispersion has two (or more) domains or if it is homogeneous 
(glass solution).  In some cases the maximum size of any possible domain can be estimated.  
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Pham and coworkers at GlaxoSmithKline described several NMR methods for estimating 
domain size.  Of particular interest is the T1 measurement. If the domain size is small, then 
the T1 relaxation time will be averaged between the drug and polymer.  If the domain size 
is large, then  the components will retain their individual distinctive relaxation times. Pham 
and co-workers used this approach and found to estimate that the domain sizes of non-salt 
dispersions of trehalose and dextran were in the 82nm to 55 nm range.14  More recently, 
Munson and co-workers used T1 and T1 methods to evaluate the miscibility of nifedipne 
in PVP, two non-ionic molecules. Those authors found that melt quenched nifedipine-PVP 
dispersions were homogeneous at ratios of 75:25, 60:40, and 50:50.15 Kojima and co-
workers used the T1 relaxation time to determine the domains sizes in a solid dispersion of 
mefenamic acid and Eudragit® EPO, which contains an amine group. In the dispersion, a 
single T1 was observed suggesting that the MFA and the EPO were within 200 to 300 
angstroms in the dispersion.16 
1.3.2 Stability of Amorphous Solid Dispersions 
Since their development by Sekiguchi and Obi in 1976, solid dispersions have been 
successfully used for stabilizing of amorphous APIs. While different mechanisms have 
been discussed to explain why solid dispersions can stabilize amorphous solids, the 
mechanism is still not fully understood. Generally speaking, factors such as the drug’s 
inherent recrystallization tendency, glass transition temperature (Tg), drug-polymer 
miscibility and the nature of the drug–polymer intermolecular interactions are found to 




   
1.3.2.1 Crystallization Tendency 
The drug’s inherent recrystallization tendency recently has been established as a 
very important factor for the stability of amorphous materials and it is thought to be related 
to several inherent physiochemical properties. In a study done by Taylor and co-workers, 
a correlation between the glass forming ability (GFA) and the glass stability (GS) was 
found. Differential scanning calorimetry (DSC) was utilized to explore the potential 
relationship between GFA and GS for a group of 51 organic molecules. The crystallization 
tendency was evaluated and subsequently used to categorize this set of model compounds 
into three classes on the basis of the presence or absence of detectable crystallization 
phenomenon during a closely monitored heating/cooling/heating cycle. With the principal 
component analysis (PCA) of various physiochemical descriptors molecules, the study 
showed that compounds with low molecular weight and rigid structures tended to have low 
GFA, while compounds possessing higher molecular weight and more complex structures 
are very likely to have higher GFA.19 The faster recrystallization rate for compounds with 
low GFA also indicates a close correlation between GFA and GS: high GFA-high GS; low 
GFA-low GS. All of these results can be applied to accelerate the amorphous form 
screening.   
Moreover, the crystallization tendency of the drug is also very important for the 
physical stability of binary systems. In a different study, thirty-nine drug molecules were 
paired randomly and the physical stability of the binary system was evaluated using DSC. 
The physical stability of the binary system was correlated with the physical stability of 
each component in the mixture. Three states, highly crystallizing, moderately crystallizing 
and non-crystallizing, were used to categorize the compounds and the systems. The 
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researchers found that the binary system will be stable in amorphous state if at least one of 
the compounds in the pair compounds was not highly crystalizing. However, if one 
component is highly crystallizing, the binary system is very likely to crystallize. 20 
1.3.2.2 Glass Transition Temperature (Tg) 
A high glass transition temperature (Tg) is typically considered important for the 
stability of an amorphous solid dispersion based on the concept that Tg represents a 
temperature range between high and low molecular mobility. As shown in Figure 2, the 
molecular mobility of a material can significantly influence its physical stability, and 
mobility also strongly depends on the temperature.4, 21  In a review by Hancock and 
Zografi,1 crystallization of amorphous materials is said to be primarily influenced by the 
factors which also determine the crystallization from the melt. Based on the corresponding 
equations, the authors state that the optimal nucleation, which initiate crystallization, will 
occur at the temperature that below melting point (Tm) and depends on the degree of 
supercooling. As the temperature is lowered below Tm, the closer T is to the Tg, the higher 
the degree of supercooling, the lower the molecular mobility, the higher the viscosity, and 
finally the more likely for nucleation to occur. Thus a relative high Tg  polymer can stabilize 
amorphous compounds by increasing the binary system Tg value relative to the room 
temperature, which results in a decrease in mobility and an increase in physical stability.22 
The rule of thumb is that the crystallization rate will be negligible if an amorphous material 
is stored 50 °C below its Tg. However, exceptions have been reported, a recent study shows 
that an ionic polymer, Eudragit® EPO, having a low Tg has better crystalline inhibition of 
amorphous indomethacin than that of PVP-VA and PVP K30, both of which possessing 
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higher Tg’s.23   Thus the physical stability of each individual amorphous system should be 
specifically evaluated. Even though Tg is usually regarded as an important descriptor of 
amorphous materials, it is important to keep in mind that it is difficult to directly correlate 
physical stability to the temperature relative to Tg,, especially for multi-component 
systems.24 
1.3.2.3 Miscibility 
Good miscibility between drugs and polymers is regarded as a prerequisite for 
stable binary amorphous systems. Poor miscibility between drugs and polymers will lead 
to a supersaturation state of drug in polymer, and finally result in the crystallizion of the 
drug from the initially homogeneous solid solution during storage. This can become 
especially prevalent for ASDs with high drug loadings or for those stored under high 
moisture and high temperature conditions.25-28 Several studies have shown that poor 
miscibility can lead to phase separation, many small drug-rich domains are more likely to 
precipitate compared to the homogenous drug/polymer solid solution regions.4, 29  
Therefore, phase separation is not desirable for stable ASD systems.30 
In addition, the solubility of drug in polymer can significantly influence on the 
driving force for the crystallization of amorphous drug in ASDs. The mechanism is shown 
in Figure 3. The Gibbs free energy of amorphous state is much higher than that of the 
crystalline form, and this is the reason behind the instability of amorphous materials. When 
the drug loading in an ASD is less than or equal to the saturation solubility of the drug in 
the polymer, the ASD formulation can be thermodynamically stable. When we utilize 
ASDs to formulate amorphous drugs, we aim to have high drug exposure which typically 
10 
  
   
means high drug loading. Thus, if the solubility of a crystalline drug in the polymer is high, 
we can still keep the drug amorphous stable even we use high drug loadings.31 However, 
the saturation solubility of drug in polymer is very difficult to measure. Various methods 
have been developed to predict the miscibility between drug and polymer. A recent study 
has showed a good correlation between the physical stability of amorphous telmisartan in 
ASD and Flory-Huggins interaction parameter (χ).32 Thus, the interaction parameter χ of 
the Flory–Huggins equation provides a measure of miscibility.33 Under a given 
temperature, zero, partial or complete miscible drug in polymer, can be obtained with 
strong repulsive (Flory–Huggins interaction parameter  χ >>0), weak repulsive (χ >0), or 
attractive (χ <0) interactions respectively.30 A published study measured the water vapor 
sorption isotherm of indomethacin in solid dispersions with PVP, and showed that the 
estimated interaction parameter χ between indomethacin and PVP was greater than 0.5, 
indicating that indomethacin and PVP are immiscible, in terms of χ value.34 Although this 
method is excellent in providing a quantitative measure of miscibility, it may be difficult 
to apply to unstable amorphous drugs, which readily crystallize upon water vapor 
sorption.35  It was also reported that the presence of a single glass transition temperature 
doesn’t always indicate good miscibility, nor provides information about the 
thermodynamics of mixing.31, 36  For example, the DSC thermogram of the 30 wt % 
ibuprofen–Soluplus® ASD showed a single Tg.31 However, polarized light microscopy 
showed phase separation in this ASD , which suggests the limitation of using DSC method 
to detect phase separation.31 A method that can be used as an alternative to DSC or 
measurement of the interaction parameter χ is analysis of the 1H spin–lattice relaxation 
time of ASD, which was reported in the fields of polymer alloy and polymer blends. If two 
11 
  
   
polymers are miscible, the relaxation decay of the mixture is describable by a mono-
exponential equation, whereas if they are not miscible, relaxation decay is describable by 
a bi-exponential expression.35  Solid-state NMR (SSNMR) 1H T1 and T1ρ relaxation times 
have been reported to be very useful to predict the miscibility between amorphous 
nifedipine and PVP in ASD.15 
 
Figure 3. Schematic energy cartoon indicating the amorphous and amorphous solid 
dispersions.37 
 
1.3.2.4 Intermolecular Interactions 
It has been recognized that strong intermolecular drug-polymer interactions such as 
hydrogen bonding and ionic interactions between polymer and API are very significant for 
the stabilization of the amorphous state of an API. Four most common intermolecular 
interactions in ASDs are: Van der Waals forces, dipole-dipole interaction, hydrogen bond 
12 
  
   
and ionic interactions. As shown in Table 1, these four type of interactions have totally 
different relative strength. Van der Waals forces and dipole-dipole interaction are 
negligible compared to the strength of the hydrogen bond and ionic interaction. The main 
fundamentals  for stabilization ASD by intermolecular interaction relies on whether the 
intermolecular interaction between drug/ polymer  binary systems is strong enough to 
overcome the barrier of crystal lattice energy of the crystalline state of drug or not. Stronger 
the intermolecular interactions would suggest more stable amorphous solid dispersions.38 
 
Table1. Typical bond energy and relative strength of intermolecular interactions.37 
 
 
1.3.2.4.1 Hydrogen Bond 
The hydrogen bond is arguably the most common type of intermolecular interaction 
between drug and polymer in ASDs and numerous publications have shown its significant 
impact for the stabilization of ASDs. A recent study has presented a methodology to screen 
stable ASDs based on the evaluation of the strength of hydrogen bond. The first step was 
to check the molecular geometry of a system for the potential to form hydrogen bonded. A 
structure with 5-, 6- or 7-membered rings is desired since these structures occur in 95% of 
Interaction type Bond energy (Kj/mol) Approximately relative strength  
Van de Waals force 1 1 
Dipole-dipole interaction 2-8 10 
Hydrogen bond 10-170 100 
Ionic interaction 850-1700 1000 
13 
  
   
cases of hydrogen bonding formation. The strength of hydrogen bonding was further 
evaluated based on the hydrogen bonding donor and acceptor strengths for both the drugs 
and polymers. For donors, the electronegativity of the hydrogen bonding atom is a very 
useful indicator for the strength of the hydrogen bond. Acceptor strength can be predicted 
using the pKBHX scale
39 , which represents the thermodynamically-based scale of acceptor 
basicity, originally derived from spectroscopically measured association constants of 1 : 1 
complexes with 4-fluorophenol. This methodology is very effective for evaluating the 
potential for hydrogen bond formation between drug and polymer,  as well as ionic 
interactions.40  
While it has been shown that hydrogen bonding can be an important factor in 
forming ASDs, it has also been shown that ASDs can be formed without hydrogen bonding. 
A study done by Van den Mooter and co-workers clearly demonstrated that a 
homogeneous, ASD of ketoconazole with PVP K25 can be formulated without the presence 
of hydrogen bond.41 Another study also showed that successful spray-dried ASD 
formulations of loperamide with PVP-K30 and PVP-VA64, with various drug loadings, 
could be produced without forming hydrogen bonding.42 Moreover, additional insight into 
the role of drug–polymer interaction on the physical stability of ASD was obtained with a 
study of the crystallization behavior of amorphous curcumin.43 It showed that the 
intramolecular bonding in curcumin can significantly reduce the extent of hydrogen 
bonding between the polyphenol and polymers. Thus, for compounds with structures 
similar to that of curcumin, hydrogen bonding with polymers can be in fact impeded, which 
leads to high tendency for crystallization. In addition, this study shows that ionic 
14 
  
   
interactions with Eudragit E100 were not hindered, and when formed, could significantly 
improve the physical stability of amorphous curcumin.43 
1.3.2.4.2 Acid-base Interactions 
Based on the structural properties of the ionic polymers as shown in Table 1, ionic 
interactions should also be very common in ASDs containing ionic polymers. In addition, 
the strength of an ionic interaction is much stronger than a hydrogen bond, which suggests 
better recrystallization inhibition ability with amorphous drugs. Recently, there has been 
an increasing interest of using acid-base interaction to stabilize amorphous dispersions of 
APIs. Table 2 lists some examples of the intermolecular interactions between drugs and 
ionic polymers including ionic interaction, hydrogen bond and hydrophobic interaction. 
Many studies have shown that strong acid-base interactions with ionic polymers are 
responsible for the crystallization inhibition of amorphous loperamide, indomethacin, 
resveratrol and mefenamic acid in the solid state or in supersaturated solutions.  
An ionic interaction in amorphous materials was first reported in a study from 
Zografi.44 They found that coprecipitated indomethacin (IMC) and sodium indomethacin 
(NaIMC)-IM possessed one single Tg, which was much greater than the predicted value, 
thus suggesting the formation of a stronger acid-salt interaction in the amorphous state. 
Such an interaction was further confirmed by the FTIR spectroscopic analysis. FTIR shows 
a combination of hydrogen bonding and ion-dipole interactions between the carboxylic 
group of IMC and the carboxylate anion of NaIMC, as the nature of this acid-salt 
interaction. Such special acid-salt interaction was thought to be responsible for inhibiting 
the crystallization of amorphous IMC through preventing the hydrogen-bond formation for 
15 
  
   
IMC dimers.44  Later, Weuts studied the use of polyacrylic acid (PAA) to stabilize 
amorphous loperamide and its two structurally related substances.45 FTIR study revealed a 
salt formation between the COOH-groups of PAA and the amino-groups of the basic 
compounds. Such interaction was proposed as being responsible for the high Tg values of 
the amorphous dispersions, improved physical stability, and an increase of the dissolution 
rate.45 Another pioneer study showed the effects of counter ion type on the Tg of the 
amorphous API by Towler using two model compounds, propranolol and nicardipine, 
which possess a secondary amine with a pKa of 9.5 and a tertiary amine with pKa of 8.6, 
respectively.46 The study found that Tgs of the amorphous salts were raised compared to 
that of the free base based on a number of factors. The general tendency is that counterions 
having a low pKa (and high electrophilicity index), will tend to form salts with high Tgs.
46  
Acid-base interactions have been shown to be very significant for both miscibility and 
physical stability of amorphous binary systems, and they can dominate other parameters 
such as difference solubility parameter (Δδ) and Δ Log P , molecular mobility, and 
hydrogen bonding.38 In a recent study on the efficiency of seven polymers for inhibiting 
the crystallization of eight model compounds, five ionic polymers were used and the study 
revealed some of very important aspects of acid-base interactions.47 The crystallization 
behavior study suggests that compounds with a higher crystallization tendency for the pure 
compound, will also be more difficult to stabilize using polymers, and even when 
stabilization was achieved, more polymer was required. Furthermore, polymers have 
varied range of stabilization capability, for basic compounds, acidic polymers PAA and 
PSSA performed best. However, they were extremely poor stabilizers for acidic drugs.47 
16 
  
   
Acid-base interactions were also found to influence on the supersaturation of 
amorphous APIs in ASDs. Upon dissolution, an initially high level of supersaturation is 
created. Maintaining it can lead to a significant increase in absorption as well as 
bioavailability of the drug. However, a supersaturated solution has higher Gibbs free 
energy and tends to separate the solute from solution by forming a solid phase (nucleation) 
in order to reduce the total Gibbs free energy.48 Thus the maintenance of supersaturation 
needs to be achieved by using various polymers as precipitation inhibitors from solutions 
by interfering with the drug nucleation and/or crystal growth in the solid state.17 In addition, 
high drug loadings in the solid state also can create the supersaturation state of amorphous 
APIs in polymers. Supersaturation can lead to recrystallization. As shown in Figure2, 
strong acid-base interaction could lower the Gibbs free energy of the binary amorphous 
system, thus lower the thermodynamic driving force for recrystallization and increase the 
activation energy for nucleation, and finally inhibit the nucleation process. In addition, the 
intermolecular acid-base interactions can also enable the polymer to sorb onto the crystal 
surface, thus the polymer may slow down or even prevent the crystal growth. The 
beneficial effects of acid-base interaction can maintain the supersaturation of amorphous 
APIs in polymers during manufacturing, long-term storage or dissolution.  
One study investigated the influence of polymers on the dissolution, 
supersaturation, crystallization, and partitioning of felodipine (FLD) and itraconazole 
(ITZ) in biphasic media. 48 Maximum partitioning into the organic phase was dependent 
upon the degree of supersaturation. Although the highest supersaturation of FLD was 
attained using Eudragit® EPO and HPMCAS-LF with better nucleation and crystal growth 
inhibition using the latter, higher partitioning of the drug into the organic phase was 
17 
  
   
achieved using Pharmacoat® 603 and Kollidon® VA-64 by maintaining supersaturation 
below critical nucleation. Critical supersaturation for ITZ was surpassed using all of the 
polymers, and partitioning was dependent upon nucleation and crystal growth inhibition in 
the order of Pharmacoat® 603 > Eudragit® L-100-55 > HPMCAS-LF. HME drug-polymer 
systems that prevent drug nucleation by staying below critical supersaturation are more 
effective for partitioning than those that achieve the highest supersaturation.48   
A recent study indicated that the supersaturation levels of weakly acidic and weakly 
basic APIs were improved with ionic polymers when stored under proper high 
temperatures and humidity levels as shown in Figure 3.49 The authors suggested that water 
was very likely to act as a catalyst or a medium, which can assist charge transfer between 
the counter ionic moieties. Thus, it could further inhibit precipitation of ionic drugs during 
storage or during dissolution in unfavorable pH conditions. However, the side effect of the 
exposures to extremes of these conditions is  potential chemical degradation, especially for 





   
 
 
Figure 2. Schematic representation of the Gibbs free energy of drug molecules 
present at different states. The Gibbs free energy difference between drug molecules in 
solution and critical nucleus (ΔG*) was defined as nucleation energy barrier. The Gibbs 
free energy difference between drug molecules in solution and in crystal lattice was the 





   
 
Figure 3. Application of ESASD (electrostatic stabilization of amorphous solid 
dispersions) model in the enhancement of stability and supersaturation of poorly water-









   
 Table 1. Characteristics of Ionic Polymers Relevant for Hydrogen Bonding. 
 
aH-Bonding acceptor strength was determined using the pKBHX scale.39 The strengths used the following scale: 
Weak < 0.75 < Medium <1.5 <Strong <2.25 <Very Strong.40 
bNo values were found for COOH acceptors,39  but it was approximated to ethyl acetate carbonyl. 




















Acceptor Strength (pKBHX)a 
HPMCA
S 
R–O–R 8.8 — N — Y Medium (diethylether 1.01) 
R–C(O)–O–R 2.5 — N  Y Medium (ethyl acetate 1.07) 
R–OH 1.8 — Y Strong Y Medium (ethanol 1.02) 
R–C(O)–OH 1.0 4.5 Y Very Strong Y Medium (ethyl acetate 1.07)b 
HPMCP 
 




— Y Strong Y Medium (ethanol 1.02) 
PAA R–C(O)–OH 13.9 4.2 Y Very Strong Y Medium (ethyl acetate 1.07)b 




R–C(O)–OH 5.8 4.5 Y Very Strong Y Medium (ethyl acetate 1.07)b 
R–C(O)–O–R — — N — Y Medium (ethyl acetate 1.07) 
Eudragit 
E100 
R–C(O)–O–R 10.0 — N — Y Medium (ethyl acetate 1.07) 
R3–N 5.0 8.5 N — Y Strong (triethylamine 1.98) 
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Table 2. List of Intermolecular Interactions between Drugs and Ionic Polymers in 
Amorphous Solid Dispersions. 
 
 
Drug Polymers Characterization 
Methods 




Griseofulvin HPMCAS FTIR Hydrogen bonds Improved Improved 
Fenofibrate HPMCAS 
and HPMCP 









XPS Ionic interaction through 





Loperamide PAA DSC and  FTIR Ionic interaction Improved Improved 
Aminoacetanilide PAA DSC and FTIR Ionic interaction Improved NA 
Resveratrol PAA FTIR Hydrogen bonds (weak) Worst polymer  NA 
Benzimidazole PSSA FTIR Ionic interaction Improved NA 
Lidocaine PSSA FTIR Ionic interaction Improved NA 
Indomethacin Eudragit 
EPO 
DSC and FTIR Ionic interaction Improved Improved 
Efavirenz Eudragit 
EPO 
DSC and FTIR No strong interaction Improved Improved 
Mefenamic acid Eudragit 
EPO 










acid and Na Salt 
Eudragit 
RL100 
NMR Ionic interaction only for 
free acid 




   
 
1.3.2.5 Analytical technologies for Characterization of Intermolecular Interactions 
 Different methods have been developed to predict and measure the intermolecular 
interactions like ionic interactions between ionic polymer and API in ASDs. The main 
screening methodology is using DSC to measure the Tg of ASD and compared it with the 
calculated value. If the experimental Tg is much higher than the predicted value, then it is 
worth to using other analytical techniques such as FTIR, ssNMR or XPS to further get the 
direct evidence for the intermolecular interactions such as hydrogen bond or acid-base 
interactions. 
 
1.3.2.5.1 DSC Method 
The most commonly used method is comparing the experimental Tg and estimated 





The constant K is in relation to the true densities of each component and the change 
in thermal expansivity of Tg of each component, w1 and w2 are the weight fraction of each 
component, Tg1 and Tg2 represent the Tg of each component. This equation is used predict 
Tgs of the binary amorphous systems starting from homo-component Tgs of similar 
molecular weights by applying polymer free volume theory and based on two assumptions: 
(1) ideal volume additivity of both components at Tg and (2) no specific interactions 
between the two components (ideal mixing behavior). Hence this method applies to binary 
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mixtures in which the components are fully miscible over the entire composition range. 
Couchman and Karasz developed an equation (CK) describing the glass transition behavior 
of polymer–plasticizer blends using a thermodynamic approach, resulting in an equation 
identical to the GT equation apart from the constant K: where ΔCp1 and ΔCp2 are the 
changes in specific heat capacity for each component at their respective Tgs. For many solid 
dispersion systems, the variation in Tg as a function of composition deviates from that 
predicted by the GT or CK equations. This deviation, which can be positive or negative, is 
indicative of non-ideal mixing behavior between the drug and polymer and has often been 
used as an indication of drug-carrier interactions. 24  
1.3.2.5.2 ssNMR 
In recent years, SSNMR has emerged as a powerful tool used to determine the 
structure of amorphous dispersion. 13C and 15N SSNMR are often used to examine 
hydrogen bonding between donor and acceptors.50 For example, 15N ssNMR has shown 
large upfield shifts of 80-100 ppm upon protonation of nitrogen atoms in heterocyclic 
aromatic systems while relatively smaller upfield shifts are seen for hydrogen bonding.51  
In contrast, this trend is reversed for aliphatic nitrogen atoms: the tertiary nitrogen atoms 
in piperidine groups show a 1 ppm downfield shift in sildenafil citrate.52 Recently, we 
found a downfield shift on protonation of a secondary amine nitrogen atom in lapatinib,53 
suggesting that we could take advantage of the atom specificity and selectivity of ssNMR 
to explore the potential intermolecular interactions between PSSA with model bases in the 




   
1.3.2.5.3 XPS 
X-ray photoelectron spectroscopy (XPS) is a surface sensitive technique that has 
become widely used for studying physical and chemical phenomena on the surface of 
solids. Generally speaking, intensities of core-level photoelectron peaks are used for 
quantitative analysis, and the chemically-induced binding energy (BE) shifts of core-level 
photoelectrons are used to identify chemical states (qualitative analysis). However, this 
type of analysis has not been widely applied to pharmaceutical characterization. Recently, 
several studies have indicated the benefits of using XPS for investigating intermolecular 
interactions especially for its remarkable sensitivity for distinguishing hydrogen bond and 
acid-base interactions. For example, a strong positive shift of N1s binding energy (Eb) of 
2 eV is an indicator of protonation for both an aromatic nitrogen in theophylline as well as 
the protonation of the aliphatic nitrogen in piperidine group. In contrast, for hydrogen bond, 
the positive shift of N1s binding energy (Eb) is between 1 and 2 eV. 
1.4 Tyrosine Kinase Inhibitors 
  As part of the novel small molecule and target-specific classes of anticancer 
agents, tyrosine kinase inhibitors (TKIs) are very promising and interest in this area is 
rapidly expanding. Since the first TKI drug, imatinib, was approved by the United States 
Food and Drug Administration in 2001, approximately 20 TKIs have become available in 
the market, as well as many others are investigated under different clinical phases. Most of 
these TKI have very good efficacy, however, some of them have poor or medium 
bioavailability because of their poor water solubility. For example, lapatinib ditosylate, 
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marketed by GlaxoSmithKiline under the tradename Tykerb®, is combined with other anti-
cancer agents for the treatment of patients with advanced or metastatic breast cancer. It has 
a very low water solubility of 0.007mg/ml at 25°C, which leads to a moderate 
bioavailability and incomplete oral absorption. The dose of lapatinib is 1500 mg per day 
and Ratain and Cohen published a very interesting paper entitled “The Value Meal: How 
to Save $1700 per month or more on lapatinib”54.  They reported that taking lapatinib with 
a high fat meal increased bioavailability by 325%.  They stated patients could reduce the 
dose from five 250 mg tablets to one per day by taking the drug with a high fat meal.  At 
current prices this would save the patient $1700 per month 54.They pointed out that diarrhea 
is a major toxicity of lapatinib; reducing the amount of unabsorbed drug and reducing the 
dose will reduce the incidence and severity of diarrhea.  This information suggests that a 
more bioavailable formulation that would simulate a food effect would greatly reduce the 
dose of lapatinib needed to achieve effective blood levels.  This reduction in dose may in 
turn reduce GI irritation and GI side effects of lapatinib. Because most of TKIs are 
structural related containing several basic amine groups, thus, a well- designed approach 
has the potential to improve their bioavailability and reduce side effects. 
1.5 Manufacturing Methods 
Melting and solvent evaporation are two major processes for manufacturing 
amorphous solid dispersions. The two most widely used large-scale processes in 
pharmaceutical industry are hot-melt extrusion and spray-drying.4 Spray drying was first 
originally widely used for simple drying operations to formulate bulk APIs and excipients, 
granulation, encapsulation, and pulmonary formulation.55 The characteristic of fast solvent 
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evaporation, which can lead to a rapid viscosity increase as well as kinetic trapping of API 
in polymer, makes spray-drying technology attractive to manufacture ASDs.  The four 
major stages during spray-drying process are atomization of the liquid, mixing of the liquid 
with gas, evaporation of the liquid, and finally separation of the dried fine particles from 
the dry gas. The spray-drying process is quite complex and a good understanding of the 
interplay between parameters such as inlet temperature, air flow rate, humidity, solution 
feed rate, pressure, solution concentration, and solvent type is required for the reproducible 
production of desired ASD formulations. However, this method involves the use of an 
organic solvent, which is not desired for pharmaceutical products. Hot melt extrusion, 
which is a continuous manufacturing process free from any solvent, is becoming more and 
more widely used in manufacturing ASDs in the pharmaceutical industry. The process 
involves the following stages: drug and polymer are melted, homogenized, extruded, and 
finally shaped as desired granules, sticks or powders. The important prerequisites for HME 
are the good miscibility of the drug and polymer in the molten form, and good thermal 
stability of the drug at high temperature of the process. 
 If well-designed, both well-designed spray-drying and hot-melt extrusion 
processes can lead to desired ASD products. However, the difference of these two 
processes on the ASD properties is still not well understood. One study by Van den Mooter 
indicates HMD can lead to higher mixing capability for the drug and copolymer compared 
to SD. Later, another study shows that ASD formulated by SD and HME can have different 
material properties such as morphological structure, powder densities, flow characteristics 
and surface area. In addition, spray-dried ASDs have poorer physical stability compared to 
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hot-melt extruded ASDs even though both ASDs have similar hydrogen bond strength 
measured by FT-IR and FT Raman. However, there has no study showing the different 
effects of different manufacturing processes on the intermolecular interaction (acid-base) 
between drug and polymer. In addition, there are other processes for formulating ASDs 
such as co-precipitation, freeze-drying, ball-milling, and cryo-milling, which are not well 
understood. Thus, it is very necessary to investigate how these manufacturing processes 












   
CHAPTER 2.INVESTIGATION OF DRUG-EXCIPIENT 
INTERACTIONS IN LAPATINIB AMORPHOUS SOLID 
DISPERSIONS USING SOLID-STATE NMR SPECTROSCOPY 
2.1 Abstract 
This study investigated the presence of specific drug-excipient interactions in 
amorphous solid dispersions of lapatinib (LB) and four commonly used pharmaceutical 
polymers, including Soluplus®, polyvinylpyrrolidone vinyl acetate (PVPVA), HPMCAS 
and hydroxypropylmethylcellulose phthalate (HPMCP). Based on predicted pKa 
differences, LB was hypothesized to exhibit a specific ionic interaction with HPMCP, and 
possibly with HPMCAS, while Soluplus® and PVPVA were studied as controls without 
ionizable functionality.  Thermal studies showed a single glass transition (Tg) for each 
dispersion, in close agreement with predicted values for Soluplus, PVPVA, and HPMCAS 
systems.  However, the Tg values of LB-HPMCP solid dispersions were markedly higher 
than predicted values, indicating a strong intermolecular interaction between LB and 
HPMCP. 15N solid-state NMR provided direct spectroscopic evidence for protonation of 
LB (i.e. salt formation) within the HPMCP solid dispersions.  1H T1 and 
1H T1 relaxation 
studies of the dispersions supported the ionic interaction hypothesis, and indicated multiple 
phases in the cases of excess drug or polymer.  In addition, the dissolution and stability 
behavior of each system was examined.  Both acidic polymers, HPMCAS and HPMCP, 
effectively inhibited the crystallization of LB on accelerated stability, likely owing to
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beneficial strong intermolecular hydrogen and/or specific ionic bonds with the acidic 
polymers. Soluplus® and PVPVA showed poor physical properties on stability and 
subsequently poor crystallization inhibition. 
2.2 Introduction 
Low oral bioavailability of poorly soluble drugs is one of the most challenging 
aspects in current pharmaceutical development. One of the most useful and popular 
approaches to increase apparent solubility and dissolution rate is using the amorphous 
state of a drug. Amorphous materials lack the three-dimensional long-range order 
characteristic of the crystalline state, but generally do possess some short-range order.56 
Physical properties of amorphous drugs are vastly different than their crystalline 
counterparts, including higher Gibbs free energy, enthalpy, entropy, heat capacity, and 
molecular mobility.2 While this leads to advantageous dissolution and kinetic solubility 
properties, it is often detrimental to physical and chemical stability due to the propensity 
to return to a lower energy crystalline state and greater molecular mobility.  Over the last 
two decades, solid solutions of active pharmaceutical ingredients (API) in hydrophilic 
polymers have been used to stabilize and develop many amorphous drug products, 
including numerous commercial products. Different mechanisms for stabilizing 
amorphous materials have been discussed over decades. In some cases, polymers with 
relatively high Tg values such as polyvinylpyrrolidone (PVP) have been shown to 
stabilize lower Tg compounds due to an antiplasticizing effect.
57, 58 Some systems, such as 
indomethacin and PVP, suggest that hydrogen bonding between polymer and API is the 
primary driver for stabilizing the amorphous state. Recently, a number of studies have 
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shown that ionic interactions are likely responsible for inhibiting crystallization of 
amorphous indomethacin, mefenamic acid, resveratrol, and loperamide.16, 45, 59-61 
However, few studies have evaluated the nature of ionic interactions in the amorphous 
state. Thus, there is a clear need for an investigation of this drug-polymer salt in 
amorphous solid dispersion.  In the aforementioned reports, infrared spectroscopy is the 
generally accepted method for detecting and characterizing possible drug-polymer 
interactions.  Here we have aimed to take advantage of the selectivity and atomic-level 
specificity of solid-state NMR spectroscopy (ssNMR) to show clear evidence of salt 
formation in amorphous dispersions containing lapatinib. 
In recent years, SSNMR has emerged as a powerful tool to determine the structure 
of amorphous dispersion. 13C and 15N ssNMR are often used to examine hydrogen bonding 
between donor and acceptors.62 In addition, utilization of T1 relaxation individually or 
combined with T1 measurements has been used to provide important information on 
whether the dispersion has two (or more) domains or is homogeneous (glass solution).  
Vogt and coworkers explored several ssNMR methods to estimate domain size.  Of 
particular interest is the T1 measurement. If the domain size is small, then the T1 relaxation 
time will be averaged between the drug and polymer.  If the domain size is large the 
components will retain their individual distinctive relaxation times. They used this 
approach to estimate that the domain sizes of non-salt dispersions of trehalose and dextran 
were in the 82 nm to 55 nm range.63  More recently, Kojima and co-workers used the T1 
relaxation time to determine the domains sizes in a solid dispersion of mefenamic acid and 
Eudragit® EPO, which contains an amine group. In the dispersion, a single T1 was observed 
suggesting that the mefenamic acid and the EPO were within 200 to 300 angstroms in the 
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dispersion.16 Munson and co-workers used T1 and T1 methods to evaluate the miscibility 
of nifedipne in PVP, two other non-ionic molecules. They found that melt quenched 
nifedipine-PVP dispersions were homogeneous at ratios of 75:25, 60:40, and 50:50.15 
Lapatinib (LB), a member of the 4-anilinoquinazoline class of kinase inhibitors, is 
marketed as the ditosylate salt by GlaxoSmithKline under the tradename Tykerb®.  This 
therapy is typically combined with other anti-cancer agents for the treatment of patients 
with advanced or metastatic breast cancer.  LB is a yellow solid with very poor water 
solubility of 0.007 mg/mL at 25 °C.  The low aqueous solubility of LB leads to incomplete 
oral absorption and moderate bioavailability, which is similar in many respects to at least 
six marketed tyrosine kinase inhibitors that also have low bioavailability. This information 
suggests that a more bioavailable formulation LB is needed and could be used as a model 
formulation for other tyrosine kinease inhibitors. 
The present work investigated the potential presence of ionic interactions between 
LB and the enteric polymers HPMCAS and HPMCP in amorphous solid dispersions. These 
interactions were investigated using various methods including DSC, 13C and 15N ssNMR.  
Dispersions in PVPVA and Soluplus were also studied as systems where hydrogen bonding 
is likely, but ionic interactions are not possible.   The effect of polymer selection on the 
dissolution and physical stability behavior of LB was examined.  Based on predicted pKa 
differences between the secondary amine of LB and phthalate groups in HPMCP (pKa = 
4.3), it was hypothesized that LB should exhibit a specific intermolecular ionic interaction 
(i.e. salt formation) in amorphous dispersions with HPMCP (Figure 1, Table 1).  In 
HPMCAS dispersions, the predicted pKa difference between the LB amine group and free 
succinate groups in the polymer is less pronounced but still in the range where salt 
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formation may be expected (pKa = 2.7).  However, accuracy in the predicted values and 
differences in the actual structural environment of succinate side chains on the polymer 
leaves open the possibilities of ionic bonding or hydrogen bonding between drug and 
polymer.  The other two polymers studied, Soluplus® and PVPVA, are good hydrogen bond 
acceptors but are non-ionizable and cannot form salts with LB.  Modulated temperature 
differential scanning calorimetry (MDSC) was used to measure glass transition 
temperatures (Tg) for each dispersion as a function of drug loading, and deviations between 
experimental and predicted Tg values were evaluated and considered in terms of the nature 
of mixing between the two components.  Solid-state NMR spectroscopy (ssNMR) was used 
to attempt to provide molecular-level confirmation of the nature of potential drug-polymer 
interactions in these systems, in particular the HPMCP system. Solid-state NMR T1 and 
T1 relaxation measurements were also utilized to probe whether or not multiple phases 
existed in the HPMCP dispersions.  Dissolution properties of LB in the solid dispersions 
were also investigated using in vitro dissolution testing under non-sink conditions.  
Additionally, the stability of the solid dispersions under accelerated storage conditions was 




   
Table 1.  Characteristics of lapatinib and polymer functional groups relevant for 
hydrogen bonding.  
 
 
aH-Bonding acceptor strength was determined using the pKBHX scale,64 and classified according to the 
following criteria: Weak < 0.75 < Medium < 1.5 < Strong < 2.25 < Very Strong.65  
bNo values were found for COOH acceptors, but it was approximated to ethyl acetate carbonyl.64 
cNo values were found for similar COOH acceptors, but it was approximated to acetophenone carbonyl.64 
dNo values given in reference 13 for secondary amines, however this is the most basic N and thus the strongest 
acceptor in lapatinib. 
eNo data available, relative strengths are estimated. 
 







Acceptor strength (pKBHX)a 
Soluplus R–C(O)–N–R2 6.6 N — Y Very Strong (1-methyl-2-
pyrrolidone 2.38) 
PVPVA R–C(O)–N–R2 4.6 N — Y Very Strong (1-methyl-2-
pyrrolidone 2.38) 
HPMCAS R–O–R 8.8 N — Y Medium (diethylether 1.01) 
 R–OH 1.8 Y Strong Y Medium (ethanol 1.02) 
 R–C(O)–OH 1 Y Strong Y Medium (ethyl acetate 1.07)b 
HPMCP 
 
2.0 Y Very 
Strong 
Y Medium (acetophenone 1.11)c 
 R–OH Negligible Y Strong Y Medium (ethanol 1.02) 
Lapatinib R-S(O)2-R 1.7 N — Y Very strong (dimethylsulfoxide: 
2.54) 
 R-NH-R 1.7 Y Weak Y Very strongd 
 
 
1.7 N — Y Weak (furan: -0.4) 
 
 
1.7 N — Y Weak (anisole: -0.05) 
 Ar-NH-Ar 1.7 Y Mediume Y Weak or mediume 
 
 
1.7 N — Y Medium (pyrimidine: 1.07) 
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Methanol and dichloromethane were provided from Macron Fine Chemicals 
(Center Valley, PA). Soluplus® and PVPVA (Kollidon VA 64) were obtained from BASF 
Corporation (Florham Park, NJ).  HPMCAS (Aqoat AS-MF) and HPMCP (HP-55) were 
purchased from the Shin-Etsu Chemical Company (Tokyo, Japan).  Lapatinib was provided 
from Attix Corporation (Toronto, Canada). Amorphous lapatinib was prepared using melt-
quenching method: melt drug in an oven at 150°C for 10 minutes and quench-cooled by 
liquid nitrogen. Phthalic acid was purchased from Alfa-Aesar (Ward Hill, MA).  
Crystalline lapatinib phthalate salt was prepared by precipitating a 1:1.1 molar ratio of LB 




   
 
 
Figure 1.  Chemical structures of (a) lapatinib and the repeating units of (b) 





Drug and polymers were dissolved in a 1:1 (v/v) mixture of DCM and methanol.  
Solutions containing LB and polymer at 2% solids (w/v) were spray dried using a Buchi 
B190 spray drier. The drug loading was varied at 10, 20, 40, 60, and 80%.  The following 
conditions were used for all samples:  aspirator flow: 400 (arbitrary units), feeding flow 





   
Polarized Light Microscopy (PLM) 
An Olympus BX-51 Optical Microscope was used to observe the crystallinity of 
samples using a 530 nm retardation plate with 100X visual magnification (a 10X objective 
with a 10X eye piece). 
Powder X-Ray Diffraction (PXRD) 
The X-ray diffraction patterns were measured using a Siemens D5000 X-
Ray diffractometer. Measurements were made using Cu K radiation. A poly (methyl 
methacrylate) set specimen holder ring was used. The data were collected at room 
temperature with a tube power of 40 kV/40 mA, scanning speed at 2 °/min, in the angular 
range of 4-40 °2 without sample rotation. 
Modulated Temperature Differential Scanning Calorimetry (MDSC) 
TA Instruments Q2000 modulated DSC equipment was used for thermal analysis. 
Samples were prepared (5–10 mg), and were heated in Tzero aluminium pans and sealed 
with Tzero aluminium lids. All samples were heated from room temperature to 120 °C with 
a heating rate of 20 °C/min. They were quickly equilibrated to 0 °C before the modulation. 
Heating rate and modulation parameters are ±0.50 °C/60 s at 3 °C/min.   All measurements 
were carried out in duplicate and results analyzed using Universal Analysis 2000 software. 
Solid-State NMR Spectroscopy (ssNMR) 
Solid-state NMR data were acquired using a Bruker Avance III HD spectrometer 
operating at 500.13 MHz for 1H, 125.77 MHz for 13C, and 50.69 MHz for 15N, along with 
a 2-channel solids probe equipped with a 4 mm spinning system.  The pulse sequence for 
13C acquisition employed ramped cross polarization (CP)66-68 with a 70-100% ramp on the 
1H channel, 5- total sideband suppression (TOSS),69, 70 and high power 1H decoupling 
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with a SPINAL6471 scheme and field strength of 89 kHz. 15N experiments utilized an 
analogous ramped CP pulse sequence, but without TOSS.  Magic-angle spinning (MAS) 
was performed at 8000 ± 3 Hz for all experiments.  The 1H 90° pulse width was 2.8 μs and 
the TOSS sequence employed 13C 180° pulses of 6.5 μs.  Each 13C and 15N experiment 
utilized a CP contact time of 5 ms, recycle delays of 2.5-5 s, depending on T1 of the sample. 
A total of 7776 scans were averaged for each 13C spectrum shown.  A total of 75000-
100000 scans were averaged for each amorphous 15N spectrum shown, 19440 scans for 
crystalline LB freebase, and 25000 scans for crystalline LB phthalate.  Line broadening of 
~10-15% of the natural line width was employed for the amorphous 15N spectra shown.  1H 
T1 (spin-lattice relaxation) measurements were made using a 
13C-detected saturation 
recovery pulse sequence modified to include TOSS, with 16 recovery delay slices ranging 
from 0.5-20 s.  1H T1 (spin-lattice relaxation in the rotating frame) measurements were 
made using a 13C-detected CP pulse sequence also modified to include TOSS.  The 1H spin-
lock time was varied from 0.05-50 ms to characterize T1, using an RF field of ~86 kHz.  
LB resonances were integrated in the range of 160-143 ppm, while HPMCP resonances 
were integrated from 90-66 ppm to calculate T1 of each respective component in the LB-
HPMCP solid dispersions.  All ssNMR data were collected at 298 K.  13C chemical shifts 
were externally referenced by setting the methyl peak of 3-methylglutaric acid to 18.84 
ppm relative to tetramethylsilane,72 while 15N chemical shifts were externally referenced 
to nitromethane by setting the amine peak of glycine to -347.58 ppm.73  Data were analyzed 





   
Dissolution 
Dissolution tests were carried out by using a Vankel system at 37 °C in 500 mL of 
0.2% (w/v) SDS in water for 2 hours.  Solid dispersions (15 mg) were put into the basket 
with a rotation speed of 100 rpm. The Vankel system was connected to a CCD array 
UV/Vis spectrophotometer (S.I. Photonics, Inc).  Every 5 minutes, concentrations were 
detected using absorbance at λ = 330 nm. The dissolution data were obtained in triplicate. 
Physical Stability Evaluation 
Solid dispersions of LB with each of the four polymers were stored at two 
conditions: 40 °C/75% RH and 25 °C/60% RH. After 3 and 6 months, samples were 
characterized by polarized light microscopy (PLM), powder X-ray diffraction (PXRD), and 
modulated temperature differential scanning calorimetry (MDSC) for crystallinity 
evaluation.  In vitro dissolution profiles were also measured. 
2.4 Results and discussion 
Characterization of Lapatinib Solid Dispersions 
Powder X-ray diffraction (PXRD) remains the gold standard method to detect 
crystallinity of a drug within amorphous solid dispersions. The PXRD pattern for 
crystalline LB shows multiple distinct peaks at 4.5, 6.8, 11.3, 15.6, 16.0, 16.9, 18.0, 20.0, 
21.3, 23.0, 24.0, 24.4, 25.5, 27.0, 27.5, 28.4, 29.0, and 30.0 °2 (Figure 2).  The presence 
of sharp, distinctive peaks for crystalline LB in the PXRD makes it relatively easy to 
identify the presence of crystalline LB in the solid dispersions.  As shown in Figure 2, the 
disappearance of all sharp peaks characteristic of crystalline LB following spray drying 
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Figure 2.  PXRD patterns of crystalline lapatinib (LB) and solid dispersions of LB 
with (a) Soluplus®, (b) PVPVA, (c) HPMCAS), and (d) HPMCP at drug loadings of 10%, 
20%, 40%, 60%, and 80%.  All amorphous dispersions were prepared by spray drying. 
 
 
Miscibility between drug and polymer is considered to be critical for the physical 
stability of any amorphous solid dispersion. Poor solubility of the amorphous drug in the 
carrier polymer within a solid dispersion may result in concentrated drug domains, which 
are much more likely to crystallize than a molecularly dispersed system during long-term 
40 
  
   
storage.74 A single observed glass transition (Tg) in the absence of a melting endotherm 
typically indicates a homogeneous amorphous system in which the drug and polymer are 
molecularly dispersed. A mixture containing nano-amorphous domains would also show a 
single Tg.
63 Thus, thermal analysis can often be conditionally used to assess the miscibility 
of two amorphous materials, and sometimes indicate intermolecular interactions between 
the drug and polymer.60, 74 MDSC measurements on solid dispersions of LB with each of 
the four polymers studied show that all dispersions exhibit a single glass transition and lack 
a melting endotherm of LB, indicating that each solid dispersion was in a molecularly 
dispersed amorphous state following preparation, at the domain size accessible via DSC 
(Figure 3). 
A number of equations exist for predicting the Tg of two amorphous materials as 
they are mixed in different ratios, including the Fox, Gordon-Taylor, and Couchman-
Karasz equations.75-78 The Couchman-Karasz equation, shown below, is used here to 
predict the Tg of binary mixtures of LB and the four polymers studied: 
   (1) 
where w1 and w2 are the weight fractions of the individual components, and CP is 
the change in heat capacity of a component between its liquid-like and glassy states. This 
method of predicting Tg of a mixture was developed on the basis of classical 
thermodynamic theory and with an assumption that the entropy of mixing in an amorphous 
mixture is purely combinatorial.79 It is also based on the additivity of free volumes of each 
individual component, which is characteristic of ideal mixing.80 Significant differences 
observed between calculated and experimental Tg values are generally taken to be due to 
lnTg =
(w1DCP lnTg )1 + (w2DCP lnTg )2
(w1DCP )1 + (w2DCP )2
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deviations from ideal behavior, and can potentially signify differences in the strengths of 
intermolecular interactions between neat individual components and those of the blend.80 
For reference, crystalline LB has a melting point of 143.5 °C. Amorphous LB, 
Soluplus®, PVPVA, HPMCAS, and HPMCP showed experimental Tg values of 48.8, 73.0, 
107.9, 120.0 and 134.0 °C, respectively. Additionally, amorphous LB, Soluplus®, PVPVA, 
HPMCAS, and HPMCP gave experimental CP values of 0.32, 0.23, 0.31, 0.24, and 0.21 
J/gK, respectively.  These Tg and CP values for each pure material were used as input to 
use the Couchman-Karasz equation to predict Tg values as a function of LB drug loading. 
Figure 3 shows a comparison between calculated and experimental Tg values as a 
function of drug loading for each system studied. Experimental Tg of LB solid dispersions 
with Soluplus® (Figure 3a), PVPVA (Figure 3b), and HPMCAS (Figure 3c) showed good 
agreement with predicted values.  Little deviation from calculated values is an indication 
of relatively ideal mixing and a lack of specific interactions between the drug and polymer. 
These data provide strong evidence that no ionic interaction is formed between LB and 
HPMCAS, where the calculated pKa of 2.7 is somewhat ambiguous in terms of the 
likelihood of salt formation, due to accuracy of the predicted values relative to the real 
examples of solid amorphous LB and succinate esters on the polymer chain.  In contrast, 
Figure 3d displays a large positive deviation between experimental and predicted Tg values 
of LB-HPMCP dispersions from 20-80% drug load. At LB drug loadings of 40% and 60%, 
the experimental Tg values exceed predicted values by more than 40 °C, a stark difference 
which could have dramatic effects on other properties, especially physical stability, of these 
relatively high drug load dispersions. The most probable explanation for this positive 
deviation from predicted values is that the binary dispersion system is non-ideal and may 
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consist of relatively strong, specific intermolecular interactions.45, 60 Such large differences 
between experimental and predicted Tg suggest that significantly more energy is needed 
for these solid dispersions to pass through the glass transition into the rubbery state. Based 
on the basic nature of LB and the acidic nature of HPMCP, we hypothesize that specific 
ionic interactions between the secondary amine of LB and phthalate groups on HPMCP 
are responsible for the marked increase in Tg values.  An amorphous LB-HPMCP salt 
would exhibit different properties than linear combinations of the two unionized 
components, and may explain the differences between experiment and prediction 




   
 
Figure 3.  Calculated and experimental Tg plotted as a function of LB weight 
fraction for solid dispersions with (a) Soluplus, (b) PVPVA, (c) HPMCAS, and (d) 
HPMCP.  Calculated values were obtained using the Couchman-Karasz equation. 
 
 
Solid-state NMR of LB-HPMCP dispersions 
While the DSC data is indicative of a specific interaction between drug and polymer 
in the LB-HPMCP dispersions, it does not lend any structural or molecular insight into the 
interaction.  In order to gain insight into the interaction between LB and HPMCP, 13C and 
15N ssNMR spectra were acquired, and 1H relaxation times were measured.  Carbon spectra, 
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shown in Figure 4, unfortunately yielded little detailed structural information on the nature 
of the interaction between LB and HPMCP due to the typically poor resolution of 
amorphous materials.  Crystalline LB freebase displays sharp resonances typical of ordered 
materials, while amorphous LB, HPMCP, and each solid dispersion showed broad, 
Gaussian resonances indicative of highly disordered materials. This is in full agreement 
with the PXRD and DSC data above.  Of note is the carbonyl peak in HPMCP, centered 
around 170 ppm, where changes in chemical shift would be expected if the phthalates in 
the polymer participated in ionic bonds with LB.  As LB drug load was increased, a new 
peak emerged at 177 ppm, which could be indicative of ionized phthalate groups.  However, 
as LB drug load increases, HPMCP content decreases, as does the signal-to-noise ratio of 
the HPMCP portion of the spectrum. This fact coupled with the inherent broad line width 
of amorphous materials makes it difficult to draw definitive conclusions from the 13C data.  
Also of interest is the small peak at 50.8 ppm, which is clearly present in the dispersions 
from 10-60% drug load, but is either absent or unresolved in the 80% drug load sample.  
We hypothesize that this peak is due to the methylene carbon adjacent to the sulfone, in 
the beta position relative to the amine nitrogen.  This peak is at 55.9 ppm in crystalline LB, 
and it is conceivable that protonating the nitrogen could change the local environment 
enough to shift this peak to 50.8 ppm, but we were not able to definitively determine this 




   
 
Figure 4.  13C CPMAS NMR spectra of crystalline LB, amorphous LB, HPMCP, 
and LB-HPMCP solid dispersions with drug loadings of 10%, 20%, 40%, 60%, and 80%. 
 
 
15N ssNMR experiments were conducted in order to take advantage of the wide 
nitrogen chemical shift range, relatively few nitrogen sites in LB, lack of nitrogen in 
HPMCP (no interference from the excipient), and sensitivity of 15N chemical shifts to 
changes in protonation state.  While these are indeed major advantages, 15N is a very low 
natural abundance nucleus with low magnetogyric ratio, and thus has extremely low 
sensitivity.  The broad lines of amorphous materials make 15N detection more difficult yet, 
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and diluting the compound of interest in an excipient further reduces signal intensity.  
Amorphous materials presented here took approximately four days each to acquire reliable 
signal-to-noise ratio.  However, despite the sensitivity limitations, nitrogen spectra 
revealed very strong spectroscopic evidence of LB-HPMCP salt formation in the 
amorphous state.  The bottom two spectra in Figure 5 show crystalline reference spectra of 
LB freebase and the LB phthalate salt.  The freebase shows a peak at -351.7 ppm, which 
represents the LB secondary amine nitrogen, and a second peak at -268.4 ppm, representing 
the aniline nitrogen.  We will focus our attention on the amine peak region, highlighted in 
gray in Figure 5.  In the LB phthalate salt, the amine peak shifts to -335.0 ppm.  For an 
aliphatic amine nitrogen, this is a large change in chemical shift and is indicative of proton 
transfer or salt formation (aromatic nitrogen atoms can show much greater chemical shift 
changes with protonation and hydrogen bonding81).  Amorphous LB shows a single broad 
resonance for the amine peak at -347.7 ppm.  However, LB solid dispersions in HPMCP 
clearly show the presence of two populations of the amine nitrogen, almost certainly due 
to ionized and unionized LB.  The additional amine peak from the protonated species in 
the HPMCP dispersions has a chemical shift of -335 to -336 ppm, which aligns well with 
the ionized amine peak in the LB phthalate salt. 
The appearance of two peaks rather than an average peak suggests the lifetimes of 
the ionized and unionized species is long on the NMR time scale.  Furthermore, the 
existence of the ionized amine almost certainly means that a solid solution of the ionized 
LB in the negatively charged polymer exists.  The ratio of unionized N peak (-348 ppm) to 
ionized N peak (-335 ppm) clearly changes as a function of drug load, in line with what 
would be expected based on the ratio of LB and phthalate functionality in HPMCP.  With 
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excess LB in the formulation, LB can occupy all accessible phthalate groups with an ionic 
interaction, and all excess LB would remain unionized.  At low drug loadings, it is expected 
that all LB would be ionized and occupy phthalate sites giving a pure solid solution.  Drug 
loadings lower than 40% were unable to be studied with 15N ssNMR due to prohibitively 
long experiment times required to achieve adequate signal-to-noise. 
Samples of LB in the other polymers at 60% drug load were also run using 15N 
ssNMR.  In each case (Soluplus®, PVPVA, and HPMCAS) no major shifting of the LB 
amine N peak was observed (data not shown).  No major shifting was expected with the 
neutral polymers Soluplus® and PVPVA, though HPMCAS afforded some ambiguity in 
the possibility of an ionic interaction.  Given the time required for each 15N ssNMR 
experiment (~4 days), lack of protonation evidence in the DSC Tg results (Figure 3c), and 
lack of LB amine peak shifting in the NMR of the 60% sample, no further 15N ssNMR 
experiments were attempted at other drug loads with HPMCAS. 
It is also worth noting that LB freebase is pale yellow in color, as are LB solid 
dispersions prepared with Soluplus®, PVPVA, and HPMCAS.  In contrast, LB phthalate is 
very bright yellow in color, as are solid dispersions prepared with HPMCP, which we feel 
adds strength to the argument of amorphous salt formation.  The color change from pale 
yellow to bright yellow is very pronounced and instantaneous when LB is mixed with 




   
 
 
Figure 5.  15N CPMAS NMR spectra of crystalline LB freebase, crystalline LB 
phthalate, amorphous LB freebase, and LB-HPMCP solid dispersions with drug loadings 










   
13C-detected 1H relaxation studies afforded sufficient resolution to determine the 
1H T1 and 
1H T1 relaxation times of both LB and HPMCP within the amorphous solid 
dispersions. The results of these relaxation studies are shown in Figure 6.  In general, a 
single phase, molecularly dispersed system should exhibit uniform 1H relaxation 
throughout the sample due to spin diffusion.  If multiple phases exist in the sample at 
sufficiently large domain sizes, proton spin diffusion will be inefficient between phase 
boundaries, and relaxation time differences may be detected in the various components of 
the sample.  For reference, amorphous LB has 1H T1 and T1 values of 2.9 ± 0.1 s and 11.2 
± 0.1 ms, while HPMCP has 1H T1 and T1 values of 2.2 ± 0.1 s and 9.5 ± 0.2 ms.  Figure 
6a shows the 1H T1 relaxation times of LB and HPMCP in solid dispersions ranging from 
10-80% drug load.  Each drug load shows uniform T1 values for both components, within 
the error of the measurement.  This indicates that the two materials are intimately mixed 
down to an estimated domain size of 95-110 nm and is consistent with the solid solution 
model.63  Figure 6b shows the 1H T1 relaxation times of LB and HPMCP, which 
interrogates a slower motional regime (kHz-order motions) than T1 (MHz-order motions).  
T1 is essentially the same at 40% drug load, but clear differences exist at both ends of the 
drug loading range.  The separation of LB and HPMCP T1 values is highly indicative of 
multiple phases existing in the solid dispersions at high and low drug loading.  This 
supports the hypothesis that at low drug loading there exists amorphous LB-HPMCP salt 
plus unionized excess HPMCP in a solid solution, while at 40% drug loading the sample 
is primarily an amorphous LB-HPMCP salt phase (a solid solution), and high drug load 
dispersions exists as some LB-HPMCP salt plus excess unionized LB.  T1 at this time 
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scale probes domain sizes down to ~7 nm,63 so it is likely that these domains of salt, excess 
unionized LB, or excess unionized HPMCP are very small and uniformly distributed 
throughout the sample.  Based on these data, it is possible to choose the optimal drug-
polymer ratio that results in a homogenous LB-HPMCP salt as an amorphous solid 
dispersion, or solid solution, without excess free amorphous lapatinib.  Based on the T1 
data, this occurs at approximately 40% drug load. 
 
 
Figure 6.  Plots of (a) 1H T1 and (b) 
1H T1 as a function of drug loading in LB-
HPMCP solid dispersions.  Error bars represent error associated in the 16-point curve 















Figure 7.  Dissolution profiles of lapatinib (LB) freebase and LB solid dispersions 
at 40% drug loading (DL40%) in Soluplus®, PVPVA, HPMCAS, and HPMCP.  The media 
was 500 mL of 0.2% (w/v) SDS in water at 37 °C. 
 
 
Figure 7 shows the dissolution profiles of LB freebase and solid dispersions with 
Soluplus®, PVPVA, HPMCAS, and HPMCP at 40% drug loading.  In order to aid wetting 
and increase the apparent solubility of LB in the dissolution studies, 0.2% (w/v) SDS was 
added to water and used as the dissolution medium.  However, these experiments were still 
under non-sink conditions.  The dissolution of LB-HPMCAS (D120 = 80%) was 
approximately 16 times higher than that of crystalline LB freebase (D120 = 5%).  Lapatinib 
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solid dispersions with HPMCP and Soluplus® also significantly increased the release of 
LB to ~70% after 2 hours.  However, there was a drop of LB concentration from the 
Soluplus® solid dispersion after the initial spring in dissolution, indicating a possible 
recrystallization of amorphous lapatinib during the dissolution experiment.  In addition, the 
PVPVA solid dispersion only increased the release to 20% after 2 hours.  The presumed 
hydrogen bonding between LB and HPMCAS and ionic interactions between LB and 
HPMCP appear to stabilize lapatinib in its amorphous state during dissolution testing.  In 
contrast, both Soluplus® and PVPVA exhibit less favorable dissolution profiles, possibly 
due to a lack of hydrogen bond donor functionality, leading to poor ability to inhibit 





Stability studies were performed by storing amorphous solid dispersions of 
lapatinib at two conditions, 25 °C/60% RH and 40 °C/75% RH for six months. Multiple 
analytical techniques such as polarized light microscopy (PLM), PXRD, MDSC, and in 
vitro dissolution were used to evaluate the physical stability of each dispersion.  After 
storage at accelerated conditions, solid dispersions of LB with PVPVA and Soluplus® 
become saturated and sticky, making these samples very difficult to prepare for PXRD, 
DSC or dissolution testing.  Using PLM after 1 month of storage, large crystalline lapatinib 
particles were found in both LB-PVPVA and LB-Soluplus® solid dispersions with 40% 
drug loading.  However, no crystallinity was observed in either LB-HPMCAS or LB-
HPMCP solid dispersions at 40% drug loading, after 6 months of storage at both conditions.  
Figure 8 shows the PXRD patterns from the stability study on HPMCAS and HPMCP 
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dispersions, and confirm that these dispersions were physically stable for up to 6 months 
at 40 °C/75% RH.  Glass transition temperatures were also measured for 40% LB in 
HPMCAS and HPMCP at stability condition and were found to not change significantly 
up to 6 months (Table 2).  The stability studies show that Soluplus® and PVPVA do not 
work well to stabilize amorphous dispersions of lapatinib.  However, HPMCAS and 
HPMCP were shown to perform very well to stabilize amorphous solid dispersions of 
lapatinib at 40% drug load, likely via hydrogen bonding interactions with HPMCAS and 




Figure 8.  PXRD patterns of lapatinib (LB) solid dispersions in (a) HPMCAS, and 
(b) HPMCP at 40% drug load.  Stability samples stored at 25 °C/60% RH and 40 °C/75% 





   
Table 2.  Glass transition temperature (Tg) of lapatinib solid dispersions under 
accelerated conditions. 













90.4 90.2 88.7 91.3 91.6 
LB-HPMCP 
40:60 
130.5 130.1 129.5 129.1 128.9 
 
2.5 Conclusion 
Spray drying was an effective method to prepare amorphous dispersions of 
lapatinib with four widely employed pharmaceutical polymers: Soluplus®, PVPVA, 
HPMCAS, and HPMCP at various drug loads.  As expected, the dissolution rate of LB was 
dramatically improved by forming solid dispersions with Soluplus®, HPMCAS, and 
HPMCP, however the PVPVA dispersion exhibited a much lesser benefit.  Stability studies 
showed that HPMCAS and HPMCP successfully inhibited the crystallization of amorphous 
lapatinib, even under accelerated conditions.  DSC Tg measurements on LB dispersions in 
Soluplus®, PVPVA, and HPMCAS showed good agreement with predicted values, but 
showed a strong positive deviation from predicted values in HPMCP dispersions.  The lack 
of indication of a specific ionic interaction between HPMCAS and LB points to hydrogen 
bonding as the likely stabilization mechanism.  However, a large positive deviation 
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between experimental Tg values of LB-HPMCP solid dispersions and predicted values 
suggests a strong ionic interaction between LB and HPMCP, consistent with the pKa 
difference between drug and polymer.  Solid-state NMR was used to further investigate the 
reason behind the elevated Tg values in HPMCP dispersions at moderate to high drug 
loadings.  Specifically, 15N ssNMR provided direct spectroscopic evidence of an ionic 
interaction between LB and HPMCP, showing two distinct populations for the amine group 
in LB.  This interaction is likely the key driver in the ability of this polymer to stabilize 
amorphous lapatinib, especially at elevated drug loadings.  1H T1 measurements supported 
the hypothesis of a salt phase as well as excess unionized LB and HPMCP at high and low 
drug loads, respectively.  Solid-state NMR also showed the optimal drug-polymer ratio at 
which one homogeneous LB-HPMCP salt (solid solution) could be formed, at 40% drug 
load. This amorphous salt approach could potentially be utilized to prepare stable 
amorphous solid dispersions of ionizable molecules at the highest possible drug loads, 
which in turn could reduce dose, pill burden, and development times, while improving 




   
CHAPTER 3. ACID-BASE INTERACTIONS OF 
POLYSTYRENE SULFONIC ACID IN AMORPHOUS SOLID 
DISPERSIONS USING A COMBINED UV/FTIR/XPS/SSNMR 
STUDY 
3.1Abstratct 
This study investigates the potential drug-excipient interactions of polystyrene sulfonic 
acid (PSSA) and two weakly basic anticancer drugs, lapatinib (LB) and gefitinib (GB), in 
amorphous solid dispersions. Based on the strong acidity of the sulfonic acid functional 
group, PSSA was hypothesized to exhibit specific intermolecular acid-base interactions 
with both model basic drugs. Ultraviolet (UV) spectroscopy revealed red shifts, which 
correlated well with the color change observed in lapatinib-PSSA solutions. Fourier 
transform infrared (FTIR) spectra suggest the protonation of the quinazoline nitrogen atom 
in both. X-ray photoelectron spectroscopy (XPS) detected increases in binding energy of 
the basic nitrogen atoms in both lapatinib and gefitinib, strongly indicating protonation of 
these nitrogen atoms. 15N solid-state NMR spectroscopy provided direct evidence for 
protonation of the quinazoline nitrogen atoms in both LB and GB, as well as the secondary 
amine nitrogen atom in LB and the tertiary amine nitrogen atom in GB.  Additionally, the 
dissolution and physical stability behaviors of both amorphous solid dispersions were 
examined. PSSA was found to significantly improve the dissolution of LB and GB and 
effectively inhibit the crystallization of LB and GB under accelerated storage conditions
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due to the beneficial strong intermolecular acid-base interaction between the sulfonic acid 
groups and basic nitrogen centers.  
3.2 Introduction 
With the development of high throughput screening and combinatorial chemistry, 
more than 40% of newly discovered active pharmaceutical ingredients (API) have poor 
aqueous solubility which may lead to low oral bioavailability.82 Amorphization has 
become one of the most popular and effective approaches to increase drug solubility and 
dissolution rate.6 Amorphous materials have higher enthalpy, entropy, Gibbs free energy, 
and  molecular mobility compared to their counterpart crystalline forms, because of the 
lack of long range molecular order.83 Since amorphous forms possess higher energy, they 
are prone to crystallize to a lower energy state during manufacturing, dissolution, and 
long-term storage.84  Amorphous solid dispersions, made of molecularly disperse APIs in 
hydrophilic polymers, have been extensively used to stabilize amorphous products.4 
However, there no definitive approach/mechanism for stabilizing amorphous drugs by 
solid dispersions. Some investigators have suggested that high glass transition 
temperature (Tg) polymers could stabilize amorphous drugs because of their 
antiplasticizing effects.85 In addition, many studies have shown that strong intermolecular 
interactions like hydrogen bonding86-88 and acid-base interactions16, 23, 45, 53, 65, 89, 90  between 
polymers and APIs are the driving force for inhibiting crystallization of  amorphous 
APIs. Since acid-base interactions are much stronger than hydrogen bonding, they have 
recently attracted significant interest. However, there are only a few acidic polymers 
suitable for use in oral solid dosage forms, such as hydroxypropylmethylcellulose acetate
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succinate (HPMCAS) and hydroxypropylmethylcellulose phthalate (HPMCP) poly 
(methacrylic acid-co-ethyl acrylate) or Eudragit® L, and polyacrylic acid (PAA). 
Moreover, phthalates are rapidly losing favor in pharmaceutical use due to safety concerns.  
All of these polymers contain weakly acidic functional groups, hence they are not very 
prone to protonate the weakly basic groups of many modern APIs. Thus, there is a clear 
interest for an evaluation of the feasibility of a strongly acidic polymer such as polystyrene 
sulfuric acid (PSSA), for formulating amorphous solid dispersions with weakly basic APIs. 
PSSA is currently widely used in ion exchanging and proton conducting membranes, but 
it is rarely used in pharmaceutical formulations. 
Van Eerdenbrugh and Taylor have shown that PSSA can inhibit crystallization of 
several compounds and have studied its acid-base interactions with model compounds 
using Fourier transform infrared spectroscopy (FTIR).65 FTIR spectroscopy is the most 
commonly used approach for investigating drug-polymer interactions as it is able to 
measure the vibrational changes of functional groups such as carbonyls, amines, 
carboxylates which are typically involved in hydrogen bonding or acid-base interactions.49, 
91 However, it has limitations when used in exploring more complex structures which have 
overlapping regions in the spectrum, which is often the case for modern APIs dispersed in 
polymers. Fortunately, other analytical techniques are also available to provide more 
information about drug-excipient interactions. Ultraviolet spectroscopy (UV) has been 
shown to be very useful for detecting energy level transitions of compounds containing 
conjugated structures.92 For example, a red shift in the UV spectrum has been observed for 
the ionization of isonicotinic acid93 and clofazimine.94  
X-ray photoelectron spectroscopy (XPS) is a surface sensitive technique that has 
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become widely used for studying physical and chemical phenomena on the surfaces of 
solids, but has seen only limited application in pharmaceutical research. Generally 
speaking, intensities of core-level photoelectron peaks are used for quantitative analysis, 
and the chemically-induced binding energy (BE) shifts of core-level photoelectrons are 
used to identify chemical states (qualitative analysis). XPS characterization has mainly 
been limited to relatively simple inorganic reactions and few problems relevant to organic 
materials have been approached using XPS. The major problems associated with XPS 
studies of organic materials are: i) possible radioactive damage of the sample from the X-
rays, and ii) the C 1s region, which is most informative for organic chemistry samples, is 
narrow and the photoemission peaks can overcrowd the region. Thus the XPS technique 
has not been widely applied to drug analysis. On the other hand, XPS was successfully 
used to provide the ability of hydrochloride pharmaceutical salts to induce water 
dissociation at the surface.95, 96 XPS was also critical to characterize the surface chemistry 
of peptide modified sol-gel thin films.97-99 Recently, several studies have indicated the 
potential of XPS for exploring intermolecular drug-polymer interactions.100 Of particular 
interest is the high sensitivity of XPS for the detection of the degree of proton transfer in 
acid-base systems by measuring the BE shift of the involved atoms.101, 102 For example, a 
strong N 1s shift of +2 eV towards higher BEs has been observed for both the protonation 
of an aromatic nitrogen in theophylline101 as well as the protonation of the aliphatic nitrogen 
in piperidine groups.103 
Solid-state NMR spectroscopy (ssNMR) continues to see increasing use for 
characterizing pharmaceutical formulations, particularly amorphous materials.  For 
example, 15N ssNMR has shown large upfield shifts of 80-100 ppm upon protonation of 
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nitrogen atoms in heterocyclic aromatic systems while relatively smaller upfield shifts are 
seen for hydrogen bonding.104  In contrast, this trend is reversed for aliphatic nitrogen 
atoms: the tertiary nitrogen atoms in piperidine groups show only a 1 ppm downfield shift 
in sildenafil citrate.52 In general, 15N chemical shift changes for aliphatic amines are much 
smaller than those of aromatic 15N nuclei.  Recently, authors of the present work found a 
downfield shift on protonation of a secondary amine nitrogen atom in lapatinib,53 showing 
that one could take advantage of the atomic specificity and selectivity of ssNMR to explore 
the potential intermolecular interactions between PSSA with model weakly basic 
compounds in the amorphous state. 
Based on the strong acidity of sulfonic acid sidechain groups in PSSA, we 
hypothesized the potential for an acid-base interaction between PSSA and nitrogen atoms 
in both lapatinib and gefitinib. We further hypothesized that this strong intermolecular 
interaction would effectively inhibit recrystallization during storage and dissolution. The 
present study investigates the potential drug-excipient interactions in amorphous solid 
dispersions using a combined UV, FTIR, XPS, 13C and 15N ssNMR study. Dissolution 
properties of LB and GB in the solid dispersions were tested in vitro under non-sink 
conditions using pH-neutral medium. The physical stability of the solid dispersions was 
also evaluated under accelerated storage conditions with powder X-ray diffraction (PXRD) 




   
Table 2.  Characteristics of PSSA and model compounds functional groups relevant 
for hydrogen bonding.  
 
 
aH-bond acceptor strength was determined using the pKBHX scale.105 The strengths used the following scale: 
Weak < 0.75 < Medium <1.5 <Strong <2.25 <Very Strong.65  
bNo values were found for COOH acceptors,105 but it was approximated to ethyl acetate carbonyl.  
cNo values were found for similar COOH acceptors,105 but it was approximated to acetophenone carbonyl. 
dNo values given in reference 33 for secondary amines, however this is the most basic N and thus the strongest 
acceptor in LB. 












PSSA Ar–S(O)2-OH 5.4 -1.5 Y Very 
Strong 
Y Low (methyl 
methanesulfonate:0.71) 
Lapatinib R-S(O)2-R 1.7 — N — Y Very strong 
(dimethylsulfoxide:2.54) 
R-NH-R 1.7 7.2 Y Weak Y Very strongd 
 
1.7 — N — Y Weak(furan: -0.4) 
 
1.7 — N — Y Weak (anisole: -0.05) 
Ar-NH-Ar 1.7 — Y Mediume Y Weak or mediume 
 
1.7 5 N — Y Medium (pyrimidine: 
1.07) 
Geftinib R3N 2.2 6.85 N — Y Very strongd 
Ar-NH-Ar 2.2 — Y Mediume Y Weak or mediume 
 




   
3.3 Experimental 
3.3.1 Materials 
Methanol and dichloromethane were obtained from Macron Fine Chemicals 
(Center Valley, PA). PSSA solution was purchased from Sigma-Aldrich Corporation 
(St.Louis, MO), lyophilized, and cryomilled to fine particles.  Lapatinib and lapatinib 
ditosylate were purchased from Attix Corporation (Toronto, Canada).  Gefitinib was 
purchased from TOKU-E (Bellingham, WA).   
 
Figure 1.  Chemical structures of (a) PSSA, (b) lapatinib, and (c) gefitinib. 
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3.3.3 Methods 
Rotary Evaporation 
Drug and polymers were dissolved in a 1:1 (v/v) mixture of dichloromethane 
(DCM) and methanol. Homogeneous solutions containing drug and PSSA were evaporated 
on a Buchi rotary evaporator under reduced pressure at 50°C. The drug content in solution 
was varied at 10, 20, 40, and 60%.  The evaporated samples were dried under vacuum 
overnight, then cryomilled for 2 minutes to obtain fine particles.  
Powder X-Ray Diffraction (PXRD) 
The X-ray diffraction patterns were collected by using the Siemens D5000 X-
ray diffractometer. Measurements were made using Cu K radiation. The data were 
collected at ambient temperature with a tube power of 40 kV/40 mA, scanning speed of 2 
°/min, in the angular range of 4-40 °2. 
Ultraviolet Spectroscopy (UV) 
UV spectra were obtained using a CCD array UV/Vis spectrophotometer (S.I. 
Photonics, Inc) in the wavenumber range of 250 nm to 850 nm for methanol solutions of 
defined concentration. 
Fourier Transform Infrared Spectroscopy (FTIR) 
FTIR measurements were performed using a Thermo Nicolet Nexus FTIR 
Spectrometer at room temperature with the following settings:  400 - 4000 cm-1, 128 scans, 
resolution of 2 cm-1. OMNIC software was used for analysis of the spectra. Solid 
dispersions of LB and GB with 10%, 20%, 40%, and 60% drug loading were examined 
and compared with pure amorphous drug and PSSA. In addition, solid dispersions with 
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40% drug loading were compared with pure amorphous drug/PSSA and crystalline 
drug/PSSA physical mixture of the same ratio. 
X-ray Photoelectron Spectroscopy (XPS) 
XPS data were obtained using a Kratos Axis Ultra DLD spectrometer with 
monochromic Al Kα radiation (1486.6 eV) at pass energy of 20 and 160 eV for high-
resolution and survey spectra, respectively. A commercial Kratos charge neutralizer was 
used to avoid non-homogeneous electric charge of non-conducting powder and to achieve 
better resolution. The resolution measured as full width at half maximum of the curve fitted 
C 1s and N 1s peaks was approximately 1 eV. Binding energy (BE) values refer to the 
Fermi edge and the energy scale was calibrated using Au 4f7/2 at 84.0 eV and Cu 2p3/2 at 
932.67 eV. XPS data were analyzed with CasaXPS software version 2313 Dev64 
(www.casaxps.com). Prior to data analysis, the C-C component of the C 1s peak was set to 
a binding energy of 284.8 eV to correct for charge on each sample. Curve-fitting was 
performed following a linear or Shirley background subtraction using Gaussian/Lorentzian 
peak shapes. The atomic concentrations of the elements in the near-surface region were 
estimated taking into account the corresponding Scofield atomic sensitivity factors and 
inelastic mean free path (IMFP) of photoelectrons using standard procedures in the 
CasaXPS software. 
Solid-State NMR Spectroscopy (ssNMR) 
Solid-state NMR data were acquired using a Bruker Avance III HD spectrometer 
operating at 500.13 MHz for 1H, 125.77 MHz for 13C, and 50.69 MHz for 15N, along with 
a Bruker 2-channel (HX) solids probe equipped with a 4 mm stator (Bruker BioSpin Corp., 
Billerica, MA).  The pulse sequence for 13C acquisition employed ramped cross 
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polarization (CP)66-68 with a 70-100% ramp on the 1H channel, 5- total sideband 
suppression (TOSS),69, 70 and high power 1H decoupling with a SPINAL6471 scheme and 
field strength of 89 kHz. 15N experiments utilized an analogous ramped CP pulse sequence, 
but without TOSS.  Magic-angle spinning (MAS) was performed at 8000 ± 3 Hz for all 
experiments.  The 1H 90° pulse width was 2.8 s and the TOSS sequence employed 13C 
180° pulses of 6.5 s.  Each 13C and 15N experiment utilized a CP contact time of 5 ms, 
and recycle delays of 2.5-5 s, depending on T1 of the sample. A total of 7776 scans were 
averaged for each 13C spectrum shown.  A total of 75000-100000 scans were averaged for 
each amorphous 15N spectrum shown, 19440 scans for crystalline LB freebase, and 25000 
scans for crystalline LB phthalate.  15N dipolar dephasing experiments utilized a dephasing 
time of 120 s and 4 kHz MAS.  Line broadening of ~10-15% of the natural line width 
was employed for the amorphous 15N spectra shown.  All ssNMR data were collected at 
298 K.  13C chemical shifts were externally referenced by setting the methyl peak of 3-
methylglutaric acid to 18.84 ppm relative to tetramethylsilane,72 while 15N chemical shifts 
were externally referenced to nitromethane by setting the amine peak of glycine to -347.58 
ppm.  Data were analyzed used Bruker TopSpinTM 3.2 software (Bruker BioSpin Corp., 
Billerica, MA), and relaxation data were fitted using KaleidaGraph 4.1 software (Synergy 
Software, Reading, PA). 
Dissolution 
Dissolution tests were carried out by using a Vankel dissolution apparatus at 37 °C 
in 500 mL of 0.2% (w/v) aqueous SDS for 2 hours.  Solid dispersions (15 mg) were put 
into the basket with a rotation speed of 100 rpm. Dissolution was monitored by UV 
spectroscopy (S.I. Photonics, Inc) with spectra taken every 5 minutes over the course of 
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the experiment. The absorbance at 330 nm was plotted vs. time and each experiment was 
repeated in triplicate. 
Physical Stability Evaluation 
Solid dispersions of PSSA with LB and GB of 40% drug load were stored at the 
ICH accelerated stability condition of 40 °C/75% RH. After 3 and 6 months, samples were 
characterized by powder X-ray diffraction (PXRD) to determine if crystallization occurred.   
3.4 Results and discussion 
Powder X-Ray Diffraction (PXRD) 
The crystallinity of the drugs was determined by PXRD immediately after the solid 
dispersions were prepared. The lack of distinct crystalline peaks in the PXRD is indicative 
of amorphous drug within the dispersion.  As shown in the Figure 2, all of LB and GB solid 








Figure 2.  PXRD plots of (a) LB-PSSA, and (b) GB-PSSA solid dispersions with 




As shown in the supplementary materials, lapatinib methanol solution is very clear; 
however, as PSSA is added into the solution, it develops a light green color. Since the 
absorption of UV and visible radiation corresponds to the excitation of outer electrons in 
conjugated systems, this color change suggests a significant change in the outer electrons 
in the conjugated system of lapatinib. UV spectroscopy was used to further investigate this 
color change by determining whether or not a potential red or blue shift was occurring in 
the drug-polymer solutions. As shown in Figure 3a, there is clear red-shift from 360 nm to 
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390 nm as the amount of PSSA increases in solution, which corresponds to the shift from 
a clear to light green solution. Green color can be produced by absorption at ~400 nm as 
well as ~800 nm. The UV spectrum correlates well with the observed color change in 
methanol solutions containing lapatinib.  Similar UV shifts were also detected in methanol 
solutions containing GB and PSSA. For both compounds, such UV red-shifts indicate the 
presence of strong intermolecular interactions between the quinazoline of the model 





   
 
Figure 3. UV-vis spectra of (a) LB-PSSA, and (b) GB-PSSA in methanol as the 



















Figure 4. FTIR spectra from 1550-1650 cm-1 of amorphous lapatinib (LB), 
crystalline LB-PSSA physical mixture (PM), amorphous LB-PSSA PM, LB-PSSA solid 




   
 
Figure 5. FTIR spectra from 1550-1650 cm-1 of amorphous gefitinib (GB), 
crystalline GB-PSSA physical mixture (PM), amorphous GB-PSSA PM, GB-PSSA solid 
dispersion (SD) at 40% drug load, and PSSA. 
 
 
While the fingerprint region of an IR spectrum can provide a wealth of information 
about a molecule, the inherent complexity of this region can make it difficult to tease out 
pertinent information. It is common to use simpler model compounds that contain some of 
the same functional groups to assign unknown peaks. This methodology was used to 
identify peaks that could indicate if LB and GB were protonated in the solid dispersions. 
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Literature reports indicate that pyridine has two peaks around 1600 cm-1 arising 
from aromatic C-C vibration and aromatic C-N vibration.106  As shown in the Figure 4 and 
5. For LB and GB, the region between 1580 and 1620 cm-1 clearly shows two distinct peaks 
that are likely to represent the aromatic C-C and aromatic C-N vibrations. While LB is 
protonated, in the case of the ditosylate salt, a new peak appears around 1620 cm-1 and a 
significant decrease in the peak around 1605 cm-1 is seen (Figure 4). Similar changes are 
observed in the IR spectrum of a 40% LB-PSSA solid dispersion, strongly suggesting that 
the LB is protonated in the PSSA matrix. The observed changes can be explained by a 
reduced electron density on the protonated nitrogen in the quinazoline ring system. Similar 
changes were observed in the GB IR spectrum when a solid dispersion was made with 
PSSA (Figure 5). In this case, the appearance of a new peak at 1637 cm-1 and the 
disappearance of the peak at 1620 cm-1 indicate the protonation of the quinazoline ring.  
The changes in the IR spectra of both drugs are not seen in either of the pure amorphous 
forms or in the drug:PSSA physical mixtures, suggesting that protonation is a solid-state 
reaction as a result of the manufacturing process creating a new amorphous salt. 
 
X-ray Photoelectron Spectroscopy (XPS) 
Figure 6 shows the N 1s peak in the XPS spectra of lapatinib freebase, lapatinib-
PSSA solid dispersion at 40% drug load, and lapatinib ditosylate salt. The N 1s peak of 
lapatinib was curve-fitted with two well-resolved components at 399.8 and 398.6 eV for 
secondary amine and quinazoline nitrogen, respectively. The ratio between these 
components was close to unity, which is consistent with two secondary amine nitrogen 
atoms and two pyridine nitrogen atoms in the lapatinib molecule (Figure 1). The shape of 
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the N 1s peak is different for LB-PSSA and lapatinib ditosylate (Figure 6): the spectra 
demonstrated a more complex multicomponent structure rather than just two simple 
components in the case of lapatinib freebase. New N 1s components at higher binding 
energies (BE) should be formed due to nitrogen protonation of the lapatinib molecules. The 
LB-PSSA and lapatinib ditosylate N 1s spectra were fitted with four components 
corresponding to secondary amine, quinazoline nitrogen, protonated secondary amine and 
protonated quinazoline nitrogen. The BE of the components and their relative areas are 
provided in Table 2. The protonated groups demonstrated higher BE than the 
corresponding non-protonated counterparts. The BE shift due to protonation is in the range 
of 1.7 - 2.5 eV for quinazoline nitrogen and in the range of 1.3 – 1.5 eV for the secondary 
amine.  It should be noted that protonation of the quinazoline nitrogen and secondary amine 
in the lapatinib molecule affected the BE of non-protonated groups: the N 1s components 
of the non-protonated quinazoline nitrogen and non-protonated secondary amine shifted by 
0.6 - 0.9 eV towards higher BE. This could be a reflection of the redistribution of electron 
density in the molecule, which is confirmed by the high BEs of the F 1s and Cl 2p peaks 
by 0.2 eV for lapatinib-PSSA DL40% and lapatinib-ditosylate (Figure 6). On the other 
hand, the S 2p peaks shifted by 1.0 eV towards lower BE. The similarity of changes in the 
XPS spectra of LB-PSSA and lapatinib ditosylate compared to lapatinib freebase points to 
the same doubly protonated state of lapatinib in the ditosylate salt and the amorphous 
dispersion in PSSA. 
The N 1s peaks in the XPS spectra of the gefitinib and gefitinib-PSSA solid 
dispersion at 40% drug load are shown Figure 7. The summary of the N 1s peak curve 
fitting is Table 2. The protonated quinazoline and protonated morpholine groups in 
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gefitinib exhibited higher shifts to BE of +0.6 and 2.1 eV, respectively. According to XPS 
analysis, the morpholine group was fully protonated. The appearance of the protonated 
components and the shift of the entire N 1s spectrum towards higher BE for the gefitinib-
PSSA solid dispersion points to a doubly protonated state of the gefitinib molecule in a 
similar manner as lapatinib-PSSA.  In both compounds, the non-protonated nitrogen 
groups (quinazoline and secondary amine in lapatinib; quinazoline and piperidine in 
gefitinib) shifted towards high BE by 0.6 - 0.9 and ca 0.9 eV for lapatinib and gefitinib, 
respectively. The electron levels of the halogen atoms, Cl 2p and F 1s, has similar tendency 
as well. As we speculated above, this high BE shift is likely due to re-distribution of the 
positive charge throughout the molecules and the conjugated quinazoline rings were 















   
Table 2. XPS N 1s assignments for each nitrogen atoms in lapatinib and gefitinib. 
 
 
Sample Functional group/ 
Binding energy (eV) 
/Area (%) 
Functional group/ 
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Figure 6. N1s peaks obtained from (a) lapatinib freebase, (b) lapatinib-PSSA solid 






   
 
Figure 7. XPS N 1s peaks obtained from (a) gefitinib, and (b) gefitinib-PSSA solid 







   
Solid-State NMR of PSSA Solid Dispersions 
Combined, the results from UV and FTIR strongly support the hypothesis that both 
lapatinib and gefitinib are protonated in their respective PSSA dispersions. While it is 
feasible to infer which positions are actually protonated through chemical reasoning and 
computational methods for pKa calculation, neither UV nor FTIR provide direct evidence 
for which nitrogen atoms are involved in the protonation. Like XPS, ssNMR is sensitive to 
subtle changes in the electronic environment surrounding nuclei of interest, making it an 
excellent technique for investigating the protonation sites in these systems. The 13C ssNMR 
spectra of crystalline LB, GB, PSSA and their dispersions are depicted in Figure 8. The 
results for crystalline LB and GB show sharp peaks, while PSSA and the solid dispersions 
show broad, Gaussian resonances indicative of amorphous materials. These results are 
consistent with the PXRD data. While informative, the carbon spectra do not provide 
specific information about the exact sites of drug-excipient interactions between these 
drugs and PSSA. 
Previously, we investigated the acid-base interaction between the secondary amine 
of LB and the phthalic acid groups in HPMCP by using 15N ssNMR.53 This technique was 
therefore also of interest to examine the potential acid-base interactions in PSSA solid 
dispersions. 15N solid-state NMR spectra of LB, GB, and amorphous solid dispersions in 
PSSA are shown in Figures 9 and 10. Assignment of the nitrogen peaks in LB and GB 
compared well to those previously reported in the literature for a structurally similar 
compound, E-2-Methoxy-N-(34-[3-methyl-4-(6-methyl-pyridin-3-yloxyl)-phenylamino]-
quinazolin-6-yl- allyl)-acetamide.104 For this compound, it was shown that protonation of 
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quinazoline nitrogen can induce an upfield shift of 80-100 ppm.  Indeed, the more basic 
quinazoline N nucleus of LB and GB shows large upfield shifts of 86.4 and 79.6 ppm, 
respectively, indicating the protonation is occurring on this specific nitrogen nucleus in 
each molecule. Additionally, the secondary amine N of LB shows a downfield shift of 16.6 
ppm in the LB-PSSA solid dispersion, relative to the crystalline freebase.  This is an 
excellent indication of protonation for the aliphatic secondary amine nitrogen LB, 
confirming the doubly protonated state of LB in the solid dispersion with PSSA. 
Confirmation of a doubly protonated state of gefitinib in the PSSA solid dispersion based 
on 15N solid-state NMR was somewhat more challenging, as isotropic chemical shifts alone 
were not sufficient.  It has been shown that tertiary aliphatic amines often do not have 
significantly different chemical shifts when protonated,52 and this is indeed the case with 
gefitinib.  As shown in Figure 10, the tertiary amine in the morpholine group (N4) has the 
same chemical shift (-330.8 ppm) in both the crystalline freebase and GB-PSSA solid 
dispersion.  To confirm protonation of this nitrogen, a dipolar dephasing (interrupted 
decoupling) experiment was performed on the GB-PSSA dispersion. In this experiment, 
the 1H decoupler is turned off for a short period of time before signal acquisition, 120 s 
in this case.  During this time, nitrogen nuclei strongly coupled (i.e. covalently bonded) to 
protons will dephase, or lose signal intensity, relative to non-protonated nitrogens.  If GB 
were doubly protonated, only the least basic nitrogen, N3, would remain unprotonated, and 
the three other N peaks would be reduced or disappear relative to the N3 peak.  Indeed this 
is what was observed in the dipolar dephased 15N spectrum of GB-PSSA shown in Figure 
10.  The peak for N4 shows significantly reduced intensity relative to N3, confirming 
protonation of N4.  Additionally, the quinazoline N2 shows significant dephasing, 
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confirming that its large chemical shift change is due to protonation.  N1 also shows 
complete dephasing as expected, since it is already protonated even in the neutral state of 
the molecule.  It should be noted that optimization of the dephasing time should result in 
complete disappearance of peaks for N2 and N4, but this would have required excessive 
spectrometer time.  The chemical shift change of 79.6 ppm in the quinazoline N2, coupled 
with the dipolar dephasing data for both N2 and morpholine N4, serve to confirm the 






   
 
Figure 8. 13C CPMAS NMR spectra of lapatinib (LB) freebase, LB-PSSA solid 
dispersion with 40% drug load, gefitinib (GB) freebase, GB-PSSA solid dispersion with 






   
 
Figure 9. 15N ssNMR of lapatinib (LB) freebase, LB ditosylate salt, and lapatinib-






   
 
Figure 10. 15N ssNMR spectra of gefitinib (GB) freebase, GB-PSSA amorphous 
solid dispersion at 40% drug load, and dipolar dephased spectrum of the GB-PSSA solid 
dispersion.  The dipolar dephased spectrum is scaled such that intensity of the N3 peak 












Figure 11. Dissolution testing at pH 7 of lapatinib (LB) freebase compared with the 
LB-PSSA solid dispersion at 40% drug load; and gefitinib (GB) freebase compared with 








   
Stability 
 
Figure 12. Physical stability testing via PXRD of lapatinib (LB)-PSSA solid 
dispersion at 40% drug load at t=0, 3 months, 6 months; and gefitinib (GB)-PSSA solid 
dispersion at 40% drug load at t=0, 3 months, 6 months. 
 
Figure 11 shows that PSSA solid dispersions with both LB and GB give significant 
improvements in the dissolution performance compared to their crystalline forms.  This 
shows that the amorphous salt formed between each API and PSSA results in greatly 
improved dissolution and that the drug does indeed release from the polymer in aqueous 
solution.  This solid-state ionic interaction further leads to excellent physical stability of 
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these two amorphous systems, as no crystallization was observed at 40% drug load in each 
system when stored at 40 °C/75% RH for up to 6 months (Figure 12).  
3.5 Conclusions 
Multiple spectroscopic techniques, including ultraviolet, infrared, X-ray 
photoelectron, and nuclear magnetic resonance spectroscopy all provide evidence of a 
strong, specific ionic interaction between two model weakly basic drugs, lapatinib and 
gefitinib, and the acidic polymer polystyrene sulfonic acid (PSSA).  XPS and solid-state 
NMR both provided the most specific and definitive evidence of protonation of each drug 
when dispersed in PSSA.  XPS showed differences in the N 1s binding energy populations 
caused by protonation of the two most basic nitrogen atoms in lapatinib and gefitinib.  15N 
solid-state NMR chemical shifts and dipolar dephasing data confirmed the doubly 
protonated state of each compound, as well exactly which nitrogen atoms were involved in 
the ionic interaction.  The special stability afforded by ionic interactions in amorphous solid 
dispersions is especially advantageous at moderate to high drug loads and can help reduce 






   
CHAPTER 4. INVESTIGATING THE ACID-BASE 
INTERACTIONS IN LUMEFANTRINE AMORPHOUS SOLID 
DISPERSIONS PREPARED BY SPRAY-DRYING AND HOT-
MELT EXTRUSION USING X-RAY PHOTOELECTION 
SPECTROSCOPY 
4.1 Abstract 
This study investigates the potential drug-excipient interactions in amorphous solid 
dispersions of model basic compound lumefantrine (LMN), with five acidic polymers. 
Based on the different acidity of the acidic functional groups, most of these polymers were 
hypothesized to exhibit intermolecular acid-base interactions with LMN. X-ray 
photoelectron spectroscopy (XPS) was used to measure the extent of the protonation of the 
tertiary amine in LMN by these five acidic polymers.  In addition, the extent of protonation 
of each amorphous solid dispersion were discussed in terms of polymer type, 
manufacturing process, and drug loading. The most acidic polymer, polystyrene sulfonic 
acid, PSSA, was found to be the most efficient polymer to protonate LMN because of 
beneficial superior acidity. The ranking order for the protonation extent of LMN by each 
polymer is the same for both manufacturing processes. However, for some polymers, like 
Eudragit L100-55 and HPMCP, spray-drying methods led to higher extent of protonation 
compared to hot-melt extrusion. This result is likely due to the complete solution state of 
drug and polymer during spray-drying process. Drug loading did not significantly impact 
the extent of acid-base interaction for these acidic polymer except polyacrylic acid,
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presumably because this polymer does not have excessive acidic group as other acidic 
polymer. 
4.2 Introduction 
Over the last two decades, amorphous solid dispersions (ASDs) have become an 
increasingly widespread approach to improve dissolution rate of emerging poorly water 
soluble drugs because of the development of high throughput screening and combinatorial 
chemistry 4.  However, the biggest challenge for the use of ASDs is the chemical and 
physical instability of amorphous drugs. A successful ASD formulation has the 
molecularly active pharmaceutical ingredients (APIs) molecularly dispersed into polymer 
chains, while maintaining the APIs in the amorphous state during manufacturing, 
dissolution and long-term storage 6. Many stabilization mechanisms for ASDs have been 
discussed over decades. More recently, utilizing strong intermolecular interactions such as 
acid-base interactions between drugs and polymers has attracted a good deal of interest, as 
a means for stabilizing ASDs 45, 49, 91, 107-110. 
Among the various techniques for preparing ASDs, spray-drying (SD) and hot melt 
extrusion (HME) are the two major approaches used in large scale for industrial 
manufacture 111. Each of these two methods relies on a number of processing parameters 
that allow to “tune” the properties of amorphous product. For example, the choice of 
solvent, inlet temperature, feed rate, solution concentration are key parameters for SD 112. 
In comparison, process temperature, residence time and rotation speed are very significant 
during HME processes 113, 114. However, there is little published information in the 
literature on how differently these two methods can influence on the physical attributes of 
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ASDs. One recent study showed that these two manufacturing processes can impact 
differently on the physicochemical and manufacturing properties of ASDs. Specifically, 
the processing method use can influence the extent of drug-polymer hydrogen bond 
interactions in ASDs 111. As there has been a significant surge of interests on using ionic 
polymers to stabilize amorphous drugs in ASDs, it is important to investigate how different 
manufacturing processes can influence the acid-base interactions between drugs and ionic 
polymers in ASDs. 
X-ray photoelectron spectroscopy (XPS) has demonstrated itself as a very powerful 
tool for surface chemistry characterization with a remarkable sensitivity for all elements 
with the only exceptions of hydrogen and helium. Despite limited reports on application 
examples for drug analysis, XPS has shown impressive potential for exploring 
intermolecular drug-polymer interactions in ASDs. Specifically, XPS has excellent 
sensitivity for the assessment of the protonation extent by measuring the shifts in binding 
energy (EB) of the selected atoms 
102. For example, a positive 1s N EB shift value of 2 eV 
is observed for the protonation of an aromatic nitrogen in theophylline as well as for an 
aliphatic nitrogen in the piperidine group. In contrast, a positive 1s N EB shift of 1-2 eV 
indicates the existence of hydrogen bond 115. This level of informative detail shows that 
XPS is a very effective analytical technique for acid-base interaction characterization. 
In this study, we used five acidic polymers to formulate ASDs of a poorly water 
soluble drug, lumefantrine (LMN), as model drug. The polymers used in the study include 
HPMCAS, HPMCP, poly (methacrylic acid-co-ethyl acrylate) or Eudragit L-100-55, 
polyacrylic acid (PAA), and polystyrene sulfonic acid (PSSA).The ASDs were prepared 
using both SD and HME with 20% and 40% drug loadings. We verified the amorphous 
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state of LMN by conducting powder X-ray diffraction (PXRD) analysis, and utilized SEM 
(scanning electron microscopy) to further characterize the surface morphology of the ASDs. 
Finally, we used XPS to measure the extent of protonation of LMN in each ASDs and 
explored the effects of polymer type, manufacturing processes, and drug loading on the 
dispersions obtained. Table 1 lists the relevant structural and acid-base parameters of LMN 
and the different polymers used in the study. The chemical structures of LMN and the 


















   
Table 3.  Characteristics of lumefantrine and acidic polymers functional groups 
relevant for hydrogen bonding. 
 
 
aH-bond acceptor strength was determined using the pKBHX scale.64 The strengths used the following scale: 
Weak < 0.75 < Medium <1.5 <Strong <2.25 <Very Strong.116 
 bNo values were found for COOH acceptors,64 but it was approximated to ethyl acetate carbonyl.  
cNo values were found for similar COOH acceptors, but it was approximated to acetophenone carbonyl. 64 










Lumefantrine R3–N 5.0 8.5 N — Y Strong (triethylamine 
1.98) 
HPMCAS R–O–R 8.8 — N — Y Medium (diethylether 
1.01) 
 R–C(O)–O–R 2.5 — N — Y Medium (ethyl acetate 
1.07) b 
R–OH 1.8 — Y Strong Y Medium (ethanol 1.02) 
R–C(O)–OH 1.0 4.5 Y Very 
Strong 
Y Medium (ethyl acetate 
1.07)b 
PAA R–C(O)–OH 13.9 4.5 Y Very 
Strong 




R–C(O)–OH 5.8 4.5 Y Very 
Strong 
Y Medium (ethyl acetate 
1.07)b 




2.0 2.9 Y Very 
Strong 
Y Medium (acetophenone 
1.11)c 
R–OH Negligible — Y Strong Y Medium (ethanol 1.02) 
PSSA Ar–S(O)2–
OH 
5.4  -1.5 Y Very 
Strong 




   
4.3 Experimental 
4.3.1 Materials 
Dichloromethane (DCM) and methanol were purchased from Macron Fine 
Chemicals (Center Valley, PA).    Lumefantrine was obtained from Attix Corporation 
(Toronto, Canada). HPMCAS (Aqoat AS-MF) and HPMCP (HP-55) were bought from 
Shin-Etsu Chemical Company (Tokyo, Japan).   Polyacrilic acid (PAA, MW= 450,000) 
and Polystyrene sulfonic acid were obtained from Sigma-Aldrich Corporation (St.Louis, 




Figure 1.  Chemical structures of (a) lumefantrine and the repeating units of (b) 
HPMCAS, (c) PAA, (d) Eudragit L100-55, (3) HPMCP, and (f) PSSA. 
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4.3.2 Methods 
Spray Drying 
LMN and polymers (except PAA) were completely dissolved in a 1:1 (v/v) mixture 
of DCM and methanol. The drug: polymer ratio in the solutions were 20:80 and 40:60 
(w/w). A Buchi B190 spray drier was used to spray-dry clear LMN-polymer solutions at a 
solid content of 2% (w/v) with the following condition parameters: aspirator flow: 400 
(arbitrary units), feeding flow rate: 5 mL/min, inlet temperature: 75 °C, outlet temperature: 
45 °C.  
Rotary Evaporation 
It was not possible to spray dry PAA. It was thus formulated using a different 
solvent and evaporation method, rotary evaporation. Homogeneous DCM:methanol, 1:1 
(v/v) solutions containing LMN and PAA were evaporated using a Buchi rotary evaporator 
under reduced pressure at 45°C. The drug loadings in the ASDs were 20%, and 40% (w/w).  
The evaporated ASD samples were dried under vacuum overnight, then ball-milled for 2 
min. to obtain fine particles. 
Hot-melt Extrusion 
Lumefantrine was physically mixed with each polymer in a 20 mL clear glass vial 
and blended by a mini vortex (Fisher Scientific, Waltham, MA) set as speed rate 5 for 5 
min., prior to the extrusion process. Extrusion of all LMN-polymer physical mixtures was 
conducted using a Haake Minilab extruder (Fisher Scientific, Waltham, MA) composed 
with a set of twin co-rotating screws. The screw rate and process time were set at 100 rpm 
and 25 min., respectively, for all physical mixtures. The temperature settings depended on 
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the polymer used and are shown in the Table 2.  The extruded samples were ball-milled for 
2 min. after cooling to room temperature in order to get fine particles. 
Powder X-Ray Diffraction (PXRD) 
The X-ray diffraction patterns were collected by using the Siemens D5000 X-
ray diffractometer. Measurements were made using Cu K radiation. The data were 
collected at ambient temperature with a tube power of 40 kV/40 mA, scanning speed of 2 
°/min, in the angular range of 4-40 °2. 
X-ray Photoelectron Spectroscopy (XPS) 
XPS data were obtained using a Kratos Axis Ultra DLD spectrometer with 
monochromic Al Kα radiation (1486.6 eV) at pass energy of 20 and 160 eV for high-
resolution and survey spectra, respectively. A commercial Kratos charge neutralizer was 
used to avoid non-homogeneous electric charge of non-conducting powder and to achieve 
better resolution. The resolution measured as full width at half maximum of the curve fitted 
C 1s and N 1s peaks was approximately 1 eV. Binding energy (BE) values refer to the 
Fermi edge and the energy scale was calibrated using Au 4f7/2 at 84.0 eV and Cu 2p3/2 at 
932.67 eV. XPS data were analyzed with CasaXPS software version 2313 Dev64 
(www.casaxps.com). Prior to data analysis, the C-C component of the C 1s peak was set to 
a binding energy of 284.8 eV to correct for charge on each sample. Curve-fitting was 
performed following a linear or Shirley background subtraction using Gaussian/Lorentzian 
peak shapes. The atomic concentrations of the elements in the near-surface region were 
estimated taking into account the corresponding Scofield atomic sensitivity factors and 




   





















HPMCAS 20, 40 130 25 100 
PAA 20, 40 130 25 100 
Eudragit 
L100-55 
20, 40 130 25 100 
HPMCP 20, 40 130 25 100 
PSSA 20, 40 155 25 100 
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4.4 Results and Discussion 
Scanning electron microscopy (SEM) 
SEM was used to explore the surface of the ASD samples. Figure 2 shows SEM 
microphotographs of the spray-dried and HEM samples. None of the LMN ASDs exhibit 
any discernible drug crystals on the surface of the particles, suggesting that all of them 
were in amorphous state. As expected, the spray-dried samples had particles with 
morphology with smooth surface because of the fast solvent evaporation during spray-
drying. In contrast, hot-melt extruded samples had very rough surface since all the hot-melt 
extruded samples were ball-milled for 2 min. after the HME process. Figure 2 shows SEM 




Figure 2.  SEM images of (a) LMN-PSSA with DL40% by spray-drying, and (b) 







   
Powder X-ray diffraction (PXRD) 
PXRD remains the most reliable technique for verifying the amorphous vs. 
crystalline state of solid samples. The PXRD diffractograms in Fig. 3 show the broad 
Gaussian peak (halo) characteristic of amorphous materials and lack any sharp peaks for 
all the LMN ASD samples produced. These results indicate that all the solid dispersions of 
LMN are X-ray amorphous and this result is also consistent with the visual SEM results. 
 
 
Figure 3.  PRXR images of from left to right:  (a) LMN ASDs with drug loading 
(DL) 40% by spray-drying, (b) LMN ASDs with DL 20% by spray-drying, (c) LMN ASDs 




   
X-ray Photoelectron Spectroscopy (XPS) 
XPS was used to investigate the intermolecular interactions between LMN and the 
five acidic polymers of the study. One literature report has shown the excellent sensitivity 
of this technique for the characterization of ionic interactions of the two basic compounds, 
lapatinib and gefitinib, with PSSA. The different possible variations of LMN ASDs, 
obtainable from the different combinations among parameters (two processing methods, 
two drug loadings and five polymers), were subjected to XPS.  Such an analysis space was 
chosen in order to explore these factors influence the acid-base interaction between drug 
and polymers in ASDs. The XPS results for the LMN ASDs are shown in Figs. 4 – 7.  The 
results are and summarized in Table 3. 
 
Polymer influence on acid-base interaction 
Figure 4 illustrates the extent of protonation of LMN brought about by its 
interaction with each of the polymers in ASDs produced by spray-drying. The profile at 
the bottom is the reference and corresponds plain LMN (i.e., free from any polymer). The 
peak located in the range of ~400 – 398 eV is the XPS signature of the unprotonated 
nitrogens. The XPS manifestation of the presence of protonated LMN nitrogens appears as 
a shift of the peak to the range ~402 – 401 eV. Samples containing both protonated and 
unprotonated nitrogens exhibit peaks in both locations, with their area being roughly 
proportional to the relative abundance of each species (protonated or unprotonated) present 
in the sample. 
The interaction of LMN with PSSA results in complete transformation of LMN 
from the free base to the salt. Figure 4 shows that the highest extent of protonation of LMN 
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(virtually 100%) was achieved with PSSA, the most acidic polymer of the set, which has a 
pKa value of -1.5.  Figure 4 also indicates that HPMCP and Eudragit L100-55 have roughly 
the similar efficiency of protonation of LMN. Based on the areas of the two peaks, about 
75% of LMN free base is protonated, thus Eudragit L100-55 and HMPCP, both of which 
are more weakly acidic than PSSA (see Table 1), are less efficient in forming the LMN salt 
than PSSA. However, based on pKa values, HPMCP is more acidic than Eudragit L100-
55. Interestingly, neither PAA nor HPMCAS led to a noticeable extent of LMN 
protonation, even though PAA and Eudragit L100-55 have the same pKa values. One 
possible reason is that LMN-PAA is formulated by rotary evaporation rather than spray-
drying and this may lead to different extents of protonation of LMN by PAA. The ranking 
order for LMN protonation efficiency for each acidic polymer obtained by the spray-drying 
method is: PSSA > HPMCP ≈ Eudragit L100-55 > PAA ≈ HPMCAS. This ranking order 
follows closely that of the acidity of the polymers.  Figure 5 shows XPS results for ASDs 
produced by hot melt extrusion. The ranking order for LMN protonation efficiency for each 
acidic polymer obtained by the HME method is: PSSA > HPMCP > Eudragit L100-55 ≈ 
PAA ≈ HPMCAS. The XPS results from ADSs produced by spray drying and by hot melt 
extrusion are generally consistent with each other in terms of the ranking order of LMN 
protonation efficiency for each polymer.  
There are visible differences between Figs. 4 and 5 for the spectra of HPMCP and 
Eudragit L100-55, which can be attributed to the manufacturing process. This aspect will 
be discussed in a subsequent part of this paper. In general terms however, the similar 
ranking order of LMN protonation extent in ASDs for five polymers manufactured by SD 
and HME, suggests that the acidity of polymer plays a dominant role for acid-base 
100 
  
   
interaction between the LMN and polymer in ASDs, and that the manufacturing process, 
while not immaterial, plays a secondary role. 
 
  




   
 
Figure 5.  XPS spectra of ASDs of LMN prepared by hot-melt extrusion and ball-milled 
for two minutes. 
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Influence of the manufacturing process on acid-base interactions 
Despite the similar ranking order of LMN protonation among the five acidic 
polymers used, there are some noticeable differences in the spectra between Figs. 4 and 5. 
A comparison of the XPS spectra for LMN-HPMCP formulated by SD and HME is shown 
in Fig. 6. It is clear from the data that the manufacturing method has an effect on the 
efficiency of protonation observed in the resulting ASD. When prepared by SD LMN-
HPMCP dispersion exhibits protonated LMN to an extent of about 75%. In contrast, the 
use of HME leads to a lower degree of protonation of the drug, at about 50%. Table 3 
summarizes the extent of LMN protonation obtained with the two manufacturing processes 
with the five different polymers. Eudragit L100-55 also exhibits a reduced level of 
protonating capacity with HME than with SD (15% vs 75%). The may result from these 
two polymers indicate that for some acidic polymers, SD can lead to higher extent of acid-
base interaction for LMN compared to HME. This may be the result from the fact that in 
SD, the drug polymer mixture is in liquid state to start and remains so until the last step of 
solvent evaporation, which occurs very rapidly in SD. We surmise that the liquid-phase 
mediated interaction between LMN and the acidic polymer leads to maximal chance 
(optimal mixing) for acid-base interactions during SD. In contrast, during HME, intimal 
mixing of the drug with the polymer takes place gradually and only after both the drug and 
polymer pass the melting point and glass transition temperature of the drug and polymer, 
respectively. In HME, the optimal conditions for acid-base exchange start once the mixture 
is in a super-cooled liquid state. Moreover, the super cooled liquid involved in HME has 
considerably higher viscosity than the organic solvent used in SD. The end result is that in 
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HME, the basic drug and acidic polymer have comparatively less chance to interact with 
each other, compared with the SD process.  
It is noteworthy that the effect of the manufacturing process becomes more 
important when the polymer is an acid of intermediate strength. For very strong acidic and 
for very weak acidic polymers, PSSA, PAA, and HPMCAS, the manufacturing process did 
not have any distinguishing influence. In summary, for polymers of intermediate acid 
strength like HPMCP, SD results in higher LMN protonation extent compared with HME. 
Presumably, this is so because SD involves fully liquid state of both LMN and polymers. 
When the polymer is a somewhat stronger acid like HPMCP, the difference in protonation 
extent between SD and HME is also present, although to a lesser degree. On the other hand, 
when the polymer is a strong acid like PSSA, the inherently strong tendency toward acid-
base interaction is such that it overrides the differences in mixing efficiency between SD 
and HME, leading to equally efficient extent of protonation for both processes.   One 




   




   
Effect of drug loading (DL) on acid-base interaction 
A complete acid-base exchange is most readily achievable when either the base or 
the acid is present in stoichiometric excess. In the LMN ASDs, a higher proportion of the 
polymer, relative to the amount of LMN present is expected to favor the protonation extent 
of the latter. Figure 7 shows the XPS spectra of ASDs consisting of LMN-PAA with DL 
values of 40% and 20% formulated by rotary-evaporation. It shows the protonation of 
LMN by PAA increases from 15% with the DL40% ASD to 40% in the DL20% ASD. This 
result suggests a mass action effect at work, where the increasing drug loadings result in 
increasingly insufficient acrylic acid content in PAA toward a complete acid-base 
exchange with LMN. Thus, for the polymer PAA, drug loading is an important parameter 
in terms of the degree of LMN protonation. However, for polymer Eudragit L100-55 which 
has similar acidity or more strongly acidic polymers like HPMCP and PSSA, the change 
in drug loading from 15% to 40% had no effect on the degree of LMN protonation. Even 
though Eudragit L00-55 has less acidic group content (5.8mmol/g) compared to PAA 
((13.9 mmol/g). In addition, Figure 8 showes the XPS spectra of HME formulated ASDs 
consisting of LMN-HPMCP with DL values of 40% and 20%. It also shows an impressive 
increase of extent of protonation of LMN with an increase of extent of polymer content. 
However, this phenomena is not observed for LMN-HPMCP formulated by spary-drying. 
Accordingly, the extent of acid-base interaction is dominated by other parameters such as 
polymer acidity or the manufacturing process. It is observed that both HPMCP and PSSA 
have excessive acidic functional group and thus drug loading did not have significant 
influence on the extent of acid-base interactions. Similar results were also observed for 
HMPCAS, which showed that the drug loading is not important for this weak acidic 
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polymer. Thus, only for PAA and HPMCP with one specific manufacturing process, drug 
loading is important. 
 




   
Table 3. Parameters influence for acid-base interactions in LMN formulations. 
Polymer Drug load 
(%w/w) 
Spray Drying Hot-melt Extrusion 
HPMCAS 20 0% Protonation 0% Protonation 
40 0% Protonation 0% Protonation 




























   
4.5 Conclusion 
To summarize, I have found that acidity of polymer plays a dominant role for the 
extent of acid-base interactions between LMN and five acidic polymers. On the other hand, 
for acidic polymers, Eudragit L100-55 and HPMCP, manufacturing process type is also 
very important. In general, SD will lead to higher extent of acid-base interaction than HME. 
However, for other three polymers, HPMCAS, PAA or PSSA, different manufacturing 
processes have the similar impact for LMN-polymer acid-base interactions. For drug 














   
CHAPTER 5. INVESTIGATING THE EFFECTIVENESS OF 
BALL-MILLING FOR ACID-BASE INTERACTIONS IN 
AMORPHOUS SOLID DISPERSIONS USING X-RAY 
PHOTOELECTION SPECTROSCOPY 
5.1 Abstract 
This study investigated the intermolecular interactions in amorphous solid dispersions of a 
basic compound lumefantrine, with five acidic polymers. Based on the different acidity of 
the acidic functional groups, most of these polymers were hypothesized to form acid-base 
interactions with LMN. X-ray photoelectron spectroscopy (XPS) was used to analyze the 
extent of the protonation of the tertiary amine in LMN by these polymers.  In addition, the 
extent of protonation of each amorphous solid dispersion was discussed in terms of 
polymer type, processing time, and drug loading. The most acidic polymer, polystyrene 
sulfonic acid, PSSA was found to be the most efficient polymer to protonate LMN because 
of its beneficial superior acidity. The ranking order of the protonation extent of LMN by 
each polymer is very close to that of the acidity of functional groups in the polymers. Ball 
milling time showed a significant impact in terms of the extent of protonation of LMN by 
all of five polymers. A correlation between extent of amorphous conversion and the extent 
of protonation was discussed. Drug loading also significantly influenced on the extent of 
acid-base interaction but its effect is less important compared to acidity and milling time. 
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5.2 Introduction 
Using the amorphous state of active-pharmaceutical ingredients is a very useful 
approach to overcome the poorly-water solubility challenge for the emerging number of 
new drug candidates under development. 1This is because amorphous materials do not  
possess the long-range order shown in their crystalline counterparts, which lead to higher 
free energy and mobility, and finally better aqueous solubility.2  However, these amorphous 
materials are inherently physical and chemical instable and always have the potential to 
recrystallize during manufacturing, dissolution, or storage. Amorphous solid dispersions 
(ASDs), which ideally molecularly disperse drug into polymer matrix, are often used to 
formulate and stabilize amorphous APIs. 3 The stabilization mechanism of ASDs is still a 
subject of investigation, meanwhile, there has been a great of interest in using strong 
intermolecular interaction such as acid-base interaction to stabilize ionic APIs in ASDs. 4-
10  
Spray-drying (SD) and hot melt extrusion (HME) are the two major approaches 
used in large scale industrial manufacturing of amorphous products.11 Other methods, such 
as solvent co-precipitation and supercritical fluid process are also very effective for 
formulating ASDs. Recently, milling method has shown its great potential for formulating 
ASDs with advantages of solvent-free and heat-free if the process is appropriately 
designed.11 The milling process, which is commonly used for particle size reduction, can 
also induce changes in physical state like amorphization.12 Under cryogenic conditions, 
which temperature is well controlled, the milling process is very likely to remove the 
crystal lattice structure and convert crystalline material to its amorphous state.12 Under
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temperature uncontrolled conditions, the surface defects of crystalline materials can be 
increased gradually by milling because of surface defect-induced local melting.12  A 
number of published reports have shown that parameters such as in situ milling temperature, 
are very important for the amorphization during the milling process. However, the 
correlationship between the degree of amorphization, as the result of different milling 
duration time, and the degree of drug-polymer intermolecular interaction is not well 
understood. With the current great interests in utilizing ionic polymers to stabilize 
amorphous drugs in ASDs, it is important to investigate the relationship between the degree 
of amorpization and the degree of protonation. 
X-ray photoelectron spectroscopy has shown its benefits for surface chemistry 
characterization with an incredible sensitivity for all elements except hydrogen and helium. 
Even though there are limited examples of the use of XPS for drug analysis, XPS has shown 
impressive potential for exploring intermolecular interactions in binary amorphous systems. 
Recently, the excellent sensitivity of XPS has been demonstrated for the assessment of the 
extent of protonation by measuring the shifts in binding energy (EB) of selected atoms.
13 
For example, a positive 1s N EB shift of 2 eV is observed for the protonation of both an 
aromatic nitrogen in theophylline and an aliphatic nitrogen in a piperidine group. In 
contrast, a positive 1s N EB shift of 1-2 eV can indicate the existence of hydrogen bond.
14 
This study shows that XPS is a very effective analytical technique for acid-base interaction 
characterization. 
In this study, we used five acidic polymers to formulate ASDs of a poorly water 
soluble drug, lumefantrine, with 20% and 40% drug loadings by using ball milling method. 
We assessed the amorphous state of LMN by conducting PXRD, and used XPS to measure 
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the extent of protonation of LMN in each ASDs and explored the effects of polymer type, 
manufacturing time, and drug loading. 
5.3 Experimental 
5.3.1 Materials 
Lumefantrine was purchased from Attix Corporation (Toronto, Canada). HPMCAS 
(Aqoat AS-MF) and HPMCP (HP-55) were purchased from Shin-Etsu Chemical Company 
(Tokyo, Japan).   Polyacrilic acid (PAA MW= 450000) and Polystyrene sulfonic acid were 
bought from Sigma-Aldrich Corporation (St.Louis, MI).  Eudragit®   L100-55 was obtained 





   
 
 
Figure 1.  Chemical structures of (a) lumefantrine and the repeating units of (b) 





Lumefantrine was physically mixed with each polymer in a 20ml clear glass vial 
and blended by a mini vortexter (Fisher Scientific, Waltham, MA) set as speed rate 5 for 2 
minutes prior to ball milling process. Ball milling of all LMN-polymer physical mixtures 
was conducted by an 8000 M Mixer/Mill from SPEX SamplePrep LLC, 15 Liberty Street, 
Metuchen, NJ 08840. 
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Powder X-Ray Diffraction (PXRD) 
The X-ray diffraction patterns were collected by using the Siemens D5000 X-
ray diffractometer. Measurements were made using Cu K radiation. The data were 
collected at ambient temperature with a tube power of 40 kV/40 mA, scanning speed of 2 
°/min, in the angular range of 4-40 °2. 
X-ray Photoelectron Spectroscopy (XPS) 
XPS data were obtained using a Kratos Axis Ultra DLD spectrometer with 
monochromic Al Kα radiation (1486.6 eV) at pass energy of 20 and 160 eV for high-
resolution and survey spectra, respectively. A commercial Kratos charge neutralizer was 
used to avoid non-homogeneous electric charge of non-conducting powder and to achieve 
better resolution. The resolution measured as full width at half maximum of the curve fitted 
C 1s and N 1s peaks was approximately 1 eV. Binding energy (BE) values refer to the 
Fermi edge and the energy scale was calibrated using Au 4f7/2 at 84.0 eV and Cu 2p3/2 at 
932.67 eV. XPS data were analyzed with CasaXPS software version 2313 Dev64 
(www.casaxps.com). Prior to data analysis, the C-C component of the C 1s peak was set to 
a binding energy of 284.8 eV to correct for charge on each sample. Curve-fitting was 
performed following a linear or Shirley background subtraction using Gaussian/Lorentzian 
peak shapes. The atomic concentrations of the elements in the near-surface region were 
estimated taking into account the corresponding Scofield atomic sensitivity factors and 




   
5.4 Results and discussion 
Powder X-ray diffraction (PXRD) 
PXRD still remains the best conventional technique for establishing the amorphous 
state of samples. The PXRD patterns show broad peaks after ball milling for 4.5 hours, 
which indicate that all the solid dispersions of LMN are X-ray amorphous. Figure 2 shows 
the PXRD spectra of LMN ASDs with five polymers at 20% drug loading after ball milling 
for 1 hr. This data suggests that PSSA has the best capability to convert crystalline LMN 
to its amorphous state while other four polymers are less effective. Figure 3 shows the 
PXRD spectra of LMN-HPMCP with 40% drug loading after ball milled for 1, 3 and 4.5 
hr. The results in the figure suggests that for most LMN-polymer binary system, 1h ball 
milled will not form amorphous LMN ASD. For some of the mixtures, 3 hr of milling can 




   
 
 
Figure 2.  PRXR images of from top to bottom:  (a) LMN-PSSA ASD with DL20%, 
(b) LMN-HPMCP ASD with DL20%, (c) LMN-Eudragit L100-55 ASD with DL20%, (d) 
LMN-PAA ASD with DL20%, and (e) LMN-HPMCAS ASD with DL20%. All the ASDs 






   
 
Figure 3.  PRXR images of from top to bottom:  (a) LMN-HPMCAS ASD with DL40% 
after BM for 4.5 hours, (b) LMN-HPMCAS ASD with DL40% after BM for 3hours, and 
(c) LMN-HPMCAS ASD with DL40% after BM for 1 hour. 
 
 
X-ray Photoelectron Spectroscopy (XPS) 
XPS was used to investigate the potential intermolecular interactions between LMN 
and five acidic polymers. We will show the XPS results for all LMN ASDs in Figures and 





   
Polymer influence on acid-base interaction 
Figure 4 illustrates the protonation extent of LMN by each polymer with 20% 
drug loading after ball milled for 4.5 hours. The peak centered at 399 eV represents 
the free base tertiary amine of LMN, while the new peak centered at 402 eV, which is 
3 eV higher than the free base represents the protonated tertiary amine of LMN. Thus, 
the highest protonation extent of LMN was achieved by PSSA, the most acidic 
polymer, which completely protonate LMN free base to salt.  Figure 4 also indicates 
that HPMCP, which is the second most acidic polymer, protonate 75% of LMN free 
base to salt, is less efficient than PSSA but much more efficient than other three 
(weaker) acidic polymers. PAA, HPMCAS and Eudragit, which have the similar 
acidity among them, lead to an unnoticeable extent of LMN protonation. The ranking 
order for LMN protonation efficiency for each acidic polymer formulated by ball 
milling for 4.5 hours is the following: PSSA> HPMCP>Eudragit L100-55≈PAA ≈ 
HPMCAS. This rank order matches closely with that of the acidity of the polymers.  
The same rank order of LMN protonation efficiency for the different polymers is 
obtained in ASDs generated by ball milling for the different milling times and 
different drug loadings. The influence of processing time and drug loading will be 
further discussed in the later part of this chapter. In summary, the same ranking order 
of LMN protonation extent in ASDs for five polymers with different ball milling time 
and drug loadings suggests the acidity of polymer is the single most dominant 
parameter for acid-base interaction between the LMN and polymer in ASDs. 
119 
  
   




   
Manufacturing time influence on acid-base interaction 
Noticeable differences were observed for same binary system ball milled for 
different time periods. Figure 5 shows that after ball milling for 1 hr, almost none of LMN-
PSSA binary system with DL40%, is protonated. However, LMN becomes fully protonated 
after ball milling for 3 and 4.5 hr. A comparison of the XPS spectra for LMN-HPMCP 
generated by ball milling for different time periods is shown in Figure 6. It is clear from 
the data that the ball milling time has a significant impact on the efficiency of protonation 
for HPMCP. Ball milling for 1 hour exhibits negligible protonated LMN while after 3 hr 
of ball milling, protonation  increased to an extent of about 30%, finally reaching ~50% of 
LMN protonation after 4.5 hr. An increase of protonation extent with an increase of ball 
milling time was also observed for HPMCAS, PAA and Eudragit L100-55. However, the 
extent of protonation is not evident for these three weakly acidic polymers compared to 
HPMCP and PSSA. These results suggest that the effect of acidity is more important than 
the ball milling time. 
Interestingly, there is a correlation between the extent of protonation resulting from 
the time of ball milling and the extent of amorphization. As shown in Figure 7, the LMN-
HPMCP DL40% binary system remains partially crystalline after 1 hr of ball milling, while 
3 and 4.5 hr of ball milling, complete amorphization of LMN is achieved. However, as 
discussed above, there is also an increase in the extent of LMN protonation by HPMCP 
along with an increase of milling times. This is an important observation, since it indicates 
that the amorphization and protonation occurs independently from each other during the 
milling process and that amorphization is much faster than the protonation step. 
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Figure 6. XPS spectra of LMN-HPMCP DL40% prepared by ball milling.
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Figure 7.  PRXR images of from top to bottom:  (a) LMN-HPMCP ASD with 
DL40% after BM for 4.5 hours, (b) LMN-HPMP ASD with DL40% after BM for 3hours, 
and (c) LMN-HPMCP ASD with DL40% after BM for 1 hour. 
 
 
Drug loading influence on acid-base interaction 
Different drug loadings in a binary system implies a different ratio of acid to base 
as a function of mixture composition. This is likely to significantly affect the extent of 
protonation in solid binary systems. As shown Figure 8, 20% drug loading leads to a higher 
extent of protonation of LMN for both PAA and Eudragit L100-55 after ball milling for 3 
hr, compared to 40% drug loading. Similar effect is seen with HPMCAS, which has similar 
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acidity as PAA and Eudragit L100-55. However, the effect is small compared to that 
resulting from acidity or manufacturing time effects. PSSA, which has the most acidic 
group, shows that the drug loading does not affect the extent of protonation of LMN, which 
is very likely because of the acidity influence dominant the protonation process. In 
addition, for HPMCP, as shown in Figure 9, the effect of ball milling time is more 
important than of drug loading. In summary, drug loading effect is much less important 
compared to acidity and manufacturing time effects. 
 
 
Figure 8. XPS spectra of ASDs of LMN-PAA and LMN-Eudragit L100-55 
prepared by ball milling for 3 hours with DL20% and DL40%. 
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Figure 9. XPS spectra of ASDs of LMN-HPMCP with DL20% and DL40% ball milled for 




The rank order of the protonation extent of LMN by each polymer is very close to 
that of the acidity of functional groups in the polymers suggesting that acidity is a very 
important parameter for LMN protonation. In addition, ball milling time has a significant 
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impact on the extent of protonation of LMN. The amorphous conversion process and LMN 
protonation occurs separately during the milling process but amorphous conversion is 
faster than protonation. Drug loading also significantly influenced on the extent of acid-
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